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The ability of an organism to adapt to its surrounding environment is at the essence of survival.  
In metazoa, this ability starts at the level of the individual cell, which utilizes a specialized set of 
cytoskeletal proteins to determine their overall shape and the organization of their intracellular 
protein complexes and organelles.  During embryonic development, the dynamic nature of the 
actin cytoskeleton is critical for virtually all morphogenic events requiring changes in cell shape, 
migration, adhesion, and division.  The behavior of the actin cytoskeleton is modulated by a 
myriad of accessory proteins.  Shroom3 (Shrm3) is an actin binding protein that regulates neural 
tube morphogenesis by eliciting changes in cell shape through a myosin II-dependent pathway.   
The Shroom-related gene SHROOM4 (formerly called KIAA1202) has also been implicated in 
neural development, as mutations in this gene are associated with human X-linked mental 
retardation.  To better understand the function of Shrm4 in embryonic development, the mouse 
Shrm4 gene was cloned and its protein product was characterized both in vivo and in vitro.  
Shrm4 is expressed in a wide range of tissue types during mouse development, including the 
vascular endothelium of the lung and the polarized epithelium of the neural tube and kidney.  In 
endothelial cells and embryo fibroblasts, endogenous Shrm4 co-distributes with myosin II to a 
distinct cytoplasmic population of F-actin and ectopic expression of Shrm4 in multiple cell types 
enhances or induces the formation of this actin-based structure.  This localization is mediated, at 
least in part, by the direct interaction of Shrm4 and F-actin.  The actin-binding motif of mShrm4 
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defines a novel actin-binding element that has not yet been described in other proteins.  The 
results described here suggest that mShrm4 is a regulator of the actin cytoskeleton and may play 
an important role during vertebrate development, particularly in the developing vasculature. 
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1.0  INTRODUCTION 
The cytoskeleton is essential to a variety of biological processes in every living organism ranging 
from bacteria to vertebrates.  In addition to providing a structural framework to support the cell, 
the various cytoskeletal networks of microtubules (MT), intermediate filaments, and actin 
filaments enable cells to carry out countless complex functions, including cell division, cell 
adhesion, and cell migration.  As a testament to the importance of these dynamic 
macromolecules, the proteins are highly conserved from yeast to humans, 75% for tubulin and 
87% for actin (intermediate filaments have not yet been described in yeast).  Even though these 
cytoskeletal proteins have been well documented since their initial discoveries [1-3], it was not 
until decades later that prokaryotic homologs were finally described.  FtsZ (tubulin), MreB and 
ParM (actin), and crescentin (intermediate filament) have all been recently discovered and these 
proteins share little to no sequence similarity to their eukaryotic homologs [4-7].  They do 
however fold into similar shaped proteins and often display similar biochemical dynamics, such 
as polymerizing into filamentous polymers and modulating a number of cellular processes.  
Each of the of different cytoskeletal networks is necessary for normal cell function and in 
many cases work in conjunction with each other to maintain the cell’s physiology.  Microtubules 
are perhaps best known for their role in chromosome segregation during cell division, but they 
can also provide a structural role and serve as an intracellular transport system for various 
cargos.  Intermediate filaments constitute one of the largest gene families in humans, with over 
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67 genes encoding intermediate filament proteins [8, 9].  The expression of these genes and the 
localization of the proteins are quite variable.  Many intermediate filaments play general 
structural roles, but there are also some tissue and cell specific functions for intermediate 
filaments.  For example, neurofilaments provide structure and protection to neuronal cells, 
whereas keratins play a supportive and protective role in both skin and hair.  Actin filaments are 
well known for providing structural support for cells (stress fibers for example), muscle 
contraction, and cytokinesis.  Actin is also at the heart of many other processes and will be 
discussed in greater detail in the following sections.    
1.1 REGULATION OF ACTIN DYNAMICS 
Actin filaments themselves are very dynamic and the underlying biochemistry is extremely 
interesting in its own right.  Individual actin monomers, called globular or G-actin, are small 43 
kDa proteins that exist in both ATP and ADP bound states and have an intrinsic ATPase activity.  
G-actin can polymerize into larger actin filaments (F-actin) in vivo, and at the right salt (and 
buffer) conditions, G-actin can spontaneously form filaments in vitro.  Actin filaments have an 
inherent polarity due to the directed addition of subunits (which can only be added in one 
orientation).  The fast growing or barbed (+) end is the site of net polymerization (Kd = 0.12 μM) 
while the slow growing or pointed   (-) end represents the site of net depolymerization (Kd = 0.6 
μM) [8].  This dichotomy of subunit addition at the ends of an actin filament gave rise to the idea 
of ‘treadmilling’ [9-12], where a monomer added to the barbed end will work its way towards 
the pointed end through the rapid addition of subunits to the barbed end and the subsequent 
removal of subunits from the pointed end.  Once incorporated into a filament, actin will 
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hydrolyze ATP ? ADP at a rate of 0.3 s-1 and release Pi much more slowly (0.002 s-1) [14-16].  
Much like any chemical reaction involving the addition/removal of subunits, the rate of 
polymerization and depolymerization reaches a steady-state equilibrium when the concentration 
of G-actin reaches the critical concentration.  Because actin is one of the most abundant proteins 
in the cell and it has the ability to respond quickly to changes in its environment, actin is an 
excellent candidate to elicit a number of changes within the cell, a few of which will be 
discussed later. 
1.1.1 Actin Regulatory Proteins 
In the complex environment of the cytoplasm, actin dynamics are regulated by a multitude of 
proteins.  The rate of polymerization and depolymerization of actin filaments can be manipulated 
within the cell by capping proteins, such as the multifunctional gelsolin [13] and CapZ [13], G-
actin binding proteins, including profilin and thymosin ?-4 [10], depolymerizing proteins, like 
ADF/Cofilin [11], nucleating proteins like the ARP2/3 complex and associated nucleation 
promoting factors (NPF) like WASP [12, 14, 15], as well as a host of other proteins.  The list of 
proteins that regulate actin dynamics is immense and is the source of numerous reviews [16, 17].  
The concerted efforts of these proteins allow actin filaments to respond quickly to the needs of 
the cell whether it is to rapidly assemble or disassemble filaments or to create branched networks 
of actin filaments. 
One process that elegantly synthesizes the function of a number of these actin regulatory 
proteins is the dendritic branching of filaments.  The idea of dendritic branching was proposed as 
an explanation for the branched actin network nucleated from the Arp2/3 complex [14].  It has 
since become a model for the mechanism behind cell migration and is also thought to be the 
 4 
driving force behind the Listeria model of locomotion within the cell [18-20].   
The model proposed by Mullins, et al, will be briefly described in order to illustrate how 
the actin regulatory proteins function together to rapidly rearrange the cytoskeleton.  In the 
model, the starting point assumes a pre-existing F-actin cytoskeleton within the cell.  An 
extracellular signal is relayed that causes the Arp2/3 complex to become active by binding a 
nucleating promoting factor, like WASP, and actin.  The site of Arp2/3 binding to actin 
establishes a branch point for the polymerization of subunits into a new filament.  Additionally, 
the Arp2/3-WASP complex mimics the pointed end of a filament, so the profilin bound G-actin 
subunits are rapidly being added to the barbed end of the new branch.  As the filament grows, it 
pushes on the membrane and generates enough force to displace it relative to its original 
position.  Capping protein binds to the growing barbed ends, terminating the filament growth and 
starting the depolymerization cycle.  ADF/Cofilin binds the filament and promotes the release of 
the ADP bound subunits (an indication of ‘older’ filaments).  Profilin then catalyzes the 
exchange of ADP for ATP in the monomers, thereby recharging the pool of available subunits 
for new filament growth.  The initiation of dendritic branching and its ensuing rapid dynamics 
provides an excellent mechanism to drive cell migration [21-23].  In any case, the six 
components listed above (actin, Arp2/3, WASP, capping protein, ADP/cofilin, and profilin) are 
sufficient to drive the entire branching process [19, 24].  Much like every other event in the cell, 
the actin regulatory proteins themselves are often under the regulation of other proteins via 
phosphorylation, for example, and frequently by the activity of phospholipids [25].  One family 
of actin regulatory proteins, the GTPases, will be discussed in another section. 
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1.1.2 Actin Binding Proteins 
The ability to bind to actin is by no means a unique feature and, in fact, there are many domains 
or motifs that can facilitate an interaction with actin.  A common motif frequently used by actin 
cross-linking proteins (discussed in section 1.1.3) is the calponin homology (CH) domain.  This 
domain is composed of about 100 amino acids that are typically found in tandem pairs and 
usually span about 250 amino acids [26].  The family of CH domain proteins contains calponin, 
fimbrin, ?-actinin, dystrophyn, and spectrin [27].  These proteins can either have multiple actin-
binding domains (ABD) on the same polypeptide, such as fimbrin, or they can be found on 
separate polypeptides that form dimers, such as ?-actinin or filamin [28].  Members of the CH 
family of actin-binding proteins bind to F-actin at a concave surface formed by the sub-domains 
of neighboring actin subunits [29, 30].   
The gelsolin family of actin-binding proteins, including gelsolin, severin, and villin 
utilize a 15 kDa module (found in three or six repeats) to differentially bind to both G- and F-
actin [31].  These capping/severing proteins preferentially bind to the barbed end of F-actin 
where they function to block the addition of new actin subunits.  In addition to the conserved 
module, villin contains a unique 8 kDa actin-binding motif referred to as the headpiece.  This 
domain is actually conserved among other actin binding proteins that otherwise share no 
homology [32].  Members of the cofilin and ADF family of proteins bind actin with a similar 
domain as the gelsolin family [33].  However, the site of interaction with actin is different then 
that of gelsolin [34].  Profilin is a G-actin binding protein that also uses a unique actin-binding 
site.  Profilin binds to G-actin in a way that allows the actin monomer a large amount of 
conformational flexibility [35].  It is believed that this ‘loose’ conformation facilitates the 
addition of actin monomers to the growing barbed end of an actin filament. 
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While the above examples do not have a standard or canonical actin-binding motif 
(excluding the CH domain), per se, each represents a family of proteins that share similar actin-
binding properties.  There are, however, a number of well-defined motifs that are known to bind 
to actin.  One such motif is the formin homology domain 2 (FH2), a 400 amino acid sequence 
that is found in at least 6 classes of proteins in mammals (with each class containing multiple 
family members) [36].  Formins use the FH2 domain to bind to F-actin and affect cytoskeletal 
dynamics in a number of different ways, including increasing nucleation and polymerization 
rates, as well as possessing capping activity [37].  In addition to the FH2 domain, formins have 
an FH1 domain that binds to profilin.  However, the non-conserved sequence outside of the FH 
domains provides the differential regulation of these otherwise conserved proteins.  There are 
numerous actin-binding proteins in a cell and perhaps just as many unique binding motifs.  It is 
quite striking that so many different proteins have evolved independent mechanisms to regulate 
the same structure. 
1.1.3 Mechanisms of Actin-Bundling 
There are certainly other proteins that regulate the assembly or architecture of F-actin.  In some 
cases, actin fibers need to be bundled together, often they need to be tethered to other 
intracellular structures, and sometimes they are required to assume a more rigid morphology.  
Actin bundling or cross-linking proteins are quite numerous in the cell and enable these ‘higher-
order’ structures to form [38].  First, it is important to mention how a protein could cross-link or 
bundle actin filaments.  There are two mechanisms that could facilitate bundling: the first 
proposes that a single actin-binding protein can bind to two separate actin filaments whereas the 
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second scenario indicates that the actin-binding protein can bind to a single actin filament and 
simultaneously homodimerize (Fig. 1).   
The first scenario (Fig. 1A) would allow a single actin-binding protein, fimbrin for 
example, to bind in a bimodal fashion to two separate actin filaments, thereby cross-linking the 
two.  One can then envision that a second copy of fimbrin binds elsewhere on one of those 
filaments and brings in a third actin filament and so on [39, 40].   
The second scenario (Fig. 1B) involves a protein that can bind to a single actin filament 
and then oligomerize to another F-actin bound copy of itself (?-actinin for example).  In this 
case, the protein can either dimerize before binding to actin or after.  Stress fibers are anti-
parallel arrays of contractile F-actin bundles that use the activity of myosin II for contraction and 
play an important role in cell adhesion, motility, and morphogenesis.  Myosin II decorates the F-
actin bundles in a periodic arrangement with ?-actinin and, much like the actomyosin contractile 
unit in a muscle sarcomere (reviewed in [41]), the myosin in a stress fiber is able to contract and 
create a rigid filament for use in cell migration or attachment to a focal adhesion.  The 
mechanisms of stress fiber formation are still poorly understood, however a recent study has 
revealed that there are multiple mechanisms that lead to stress fiber assembly [42].  
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                                  Figure 1: Mechanisms of Actin Bundling 
 
 
Figure 1 Mechanisms of Actin Bundling 
A.  A single actin-bundling protein (yellow, ABP) can have two separate actin-binding domains, capable 
of binding two individual filaments (1 & 2).  A second copy of ABP can bind yet a third actin filament (3) 
and by also binding to filament ‘2’ will effectively begin the bundling process.  B.  In the case of actin-
bundling proteins that have single binding domains (green, ABP), the bundling protein will bind a single 
actin filament (1) and then dimerize with another copy of ABP bound to a different filament (2).  A third 
copy of ABP can bind elsewhere on filament 2, which will then dimerize with yet a fourth copy of ABP 
bound to a separate filament (3).  In either A or B, the end result is the same: single actin filaments 
tethered together to form higher-order actin structures. 
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1.1.4 Regulation of Actin by G-proteins 
The regulation of actin dynamics is not just a simple manipulation by direct actin-binding 
proteins, but rather changes in actin dynamics are often under the direct control of signaling 
cascades that organize these cytoskeletal rearrangements.  The Rho pathway has been mentioned 
above and due to its important role in regulating actin dynamics, it deserves to be described in 
more detail [43, 44].  A classic example of the Rho pathway facilitating cytoskeletal 
rearrangements is the signaling cascade initiated by the extracellular ligand, folded gastrulation 
(fog), in Drosophila [45, 46].  In this pathway, the secreted protein fog is induced by the 
morphogen twist.  Fog then activates concertina (cta) (a G?12/13 protein), which in turn activates 
RhoGEF2.  RhoGEF2 signals to ROCK, which ultimately activates myosin II on a population of 
F-actin that is tethered to adherens junctions [47, 48].  The activated myosin II causes the 
tethered actin to contract and force the apical constriction of the cells. 
The Rho family consists of roughly 5 groups, Rho-like, Rac-like, Cdc42-like, Rnd, and 
RhoBTB subfamilies.  It is the activities of the first three groups that have been well documented 
in their regulation of actin dynamics, including stress fiber formation and membrane 
ruffling/lamellipodia formation.  Much like every other signaling pathway, the Rho pathway 
must be initiated by an external signaling mechanism to relay the requirements needed for a 
specific function, whether its trauma signaling for a wound healing response or morphogens (like 
fog) inducing cell movements.  The Rho family of GTPases can be activated by signaling 
through receptor tyrosine kinases (RTKs), lysophosphatadic acid (LPA), integrins, and cadherins 
[49-51].  Often times, the first proteins in the Rho cascade to be activated are regulatory in 
nature.  Nucleotide (guanine) exchange factors (GEFs), comprise a large family of proteins as 
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there are about 70 identified in the human genome [52].  GEFs, such as DRhoGEF2 mentioned 
above, are one of the first protein targets of the signaling cascade and they facilitate the exchange 
of GDP for GTP at the level of Rho [53, 54].  GTPase activating proteins (GAPs) function to 
enhance the intrinsic GTPase activity of a Rho-GTPase [55].  Additionally, there are guanine 
nucleotide dissociation inhibitors (GDIs), which bind to the GDP-bound RhoGTPase and inhibit 
the exchange of GTP for GDP.  All of the above Rho-family effector proteins motioned above 
are in place to regulate the balance between the active and inactive forms (GTP bound vs. GDP 
bound respectively) [56].  It is these upstream proteins that typically provide the specificity to the 
extracellular signal, as Rho and ROCK are common downstream effectors for many cytoskeletal 
rearrangements. 
In stress fiber formation, Rho functions to activate myosin II and to increase actin 
polymerization.  The Rho kinase, ROCK, is activated by binding to GTP-bound Rho [57, 58].  
Activated ROCK can then proceed to phosphorylate myosin light chain kinase (MLCK) or 
inhibit myosin phosphatase.  By activating myosin II through this cascade, a net increase in 
contractile myosin occurs resulting in stress fiber and focal adhesion formation.  Additionally, 
ROCK can activate LIM kinase, which subsequently inhibits cofilin (actin depolymerizing 
factor) [59], further supporting a net polymerization.  Rho can further enhance stress fiber 
formation by activating diaphanous (mDia), an actin nucleating factor [60].   
In a similar type of signaling mechanism, Rac can mobilize the cytoskeleton to generate 
lamellipodia or membrane ruffles.  Rac signals to a complex of proteins (collectively referred to 
as the WAVE or SCAR complex) consisting of Arp2/3 activating protein WAVE, two Rac 
binding proteins (Nap125 and PIR121), and HSPC300 and Abi2 [15, 61].  Active Rac can cause 
this complex to dissociate, de-repressing WAVE so it can functionally enhance Arp2/3 actin 
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polymerization.  Rac is also able to signal through other proteins, such as PAK, which signals to 
downstream effectors to promote actin polymerization or to at least stabilize existing filaments.  
It is not surprising that the Rho-family signaling pathways often converge and either directly 
activate each other or utilize common downstream targets to elicit a response.   
1.2 THE ROLE OF ACTIN IN CELL FUNCTION  
The biochemistry of actin and its ensuing dynamic nature place actin in a central role for most 
activities of the cell.  A few cellular processes have been described above that utilize actin 
dynamics, such as migration, but those just scratch the surface of actin’s potential.  In addition to 
those described above, F-actin provides a rigid network which serves as an anchored support that 
is central for adhesion, cell polarity, signal transduction, and vesicular transport.  Below is a brief 
description of these cellular properties and actin’s role in them. 
1.2.1 Adhesion Structures 
Many of the adhesive properties of the cell involve either direct or indirect links to F-actin.  
Whether a cell needs to be anchored to the extracellular matrix (ECM) through focal adhesions 
or form cell-cell contacts like tight junctions and adherens junctions, F-actin is at the core of 
these adhesive structures [54, 62].  The following section will briefly describe the molecular 
composition of each of these adhesion structures, and Fig. 2 depicts the various adhesion 
structures discussed. 
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1.2.1.1 Focal Adhesions 
Focal adhesions are a complex of proteins that link the ECM to the cytoplasm.  Integrins are 
transmembrane receptor proteins that simultaneously interact both with the components of the 
ECM and to a complex of cytoplasmic proteins including vinculin, talin, and paxillin among 
others (Fig. 2B).  Each of these proteins is involved in the dynamic association with actin 
filaments.  Due to the multitude of focal adhesion associated proteins, there are different types of 
focal adhesions (focal complexes, focal contacts or adhesions, and fibrillar adhesions) [63].  
These links to the ECM not only serve as adhesive sites, enable cell migration, or direct ECM 
reorganization, but they also serve as signaling centers.  Many of the proteins associated with 
focal contacts are signaling molecules, including tyrosine kinases (focal adhesion kinase or 
FAK), tyrosine phosphatases, and other adaptor proteins, that can induce cytoskeletal 
rearrangements because of their intimate link to actin filaments [63, 64].  For example, FAK can 
phosphorylate ?-actinin, which reduces stress fiber rigidity [65], or alternatively FAK can 
phosphorylate p190 RhoGEF, which increases the active myosin pool, leading to an increase in 
stress fiber rigidity [66, 67]. 
1.2.1.2 Tight Junctions 
Similarly, the junctional complexes, consisting of tight junctions (TJ) (subapical complex in 
Drosophila) and adherens junctions (AJ), form adhesive structures that enable cells to link 
together (the ‘epithelial junctional complex’ or more commonly known as the apical junctional 
complex (AJC)). Tight and adherens junctions provide a mechanism of creating a selective 
cellular barrier between two spaces, such as the epithelial layer lining the gut or the endothelium 
that comprise the vasculature.  When necessary, these barriers are able to allow the passage of 
small molecules, either through the cells or in between them. The arrangement of the junctions 
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within the cell create an inherent polarity (apical to basal), and it is this polarity that helps the 
cells to adhere to each other and to form the gated barrier that separates the external world from 
the internal one.  Of course these junctional complexes must also be dynamic, and there are a 
number of signaling molecules associated that can respond to external signals and elicit changes 
within the cell [68] (Fig. 2A).  
TJs, the apical most adhesive structures, are comprised of the multi-pass transmembrane 
proteins occludin [69] or claudin (over 24 identified) [70], or the junctional adhesion molecules 
(JAM) 1-4 [71], plus a number of scaffolding and signaling proteins [72, 73].  Among these are 2 
well-known complexes, the Crumbs-PALS1 (Stardust)-PATJ complex and the PAR3 (Bazooka)-
PAR6-aPKC complex (= Drosophila homologue).  The proteins of these two complexes are 
either signaling molecules themselves (aPKC) or recruit and bind directly to other signaling 
molecules (PAR6 can bind to cdc42 for example).  TJs also contain other scaffolding proteins 
such as zonula occludens -1, -2, -3 (ZO), cingulin, and many other PDZ containing proteins.  
PDZ motifs (PSD-95, Discs-large A, and ZO-1 being the founding members) facilitate protein-
protein interactions and help to organize large protein complexes [74-77].  In general, PDZ 
domains consist of about 90 amino acids that contain a conserved GLGF peptide sequence [78, 
79].  F-Actin binds directly to the TJ proteins occludin, cingulin, and the ZO proteins, again 
placing F-actin at the center of yet another adhesion structure.  Regulation of actin dynamics 
could originate through any number of signaling molecules that have also been reported to be 
associated with TJs, including the Ras, Rab, and Rho-family of GTPases.  These cytoskeletal 
rearrangements could be in response to an internal or external signal and could function to help 
mobilize an epithelial cell or to regulate paracellular permeability [80].   
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1.2.1.3 Adherens Junctions 
Adherens junctions (Fig 2B) are conceptually similar to focal adhesions and TJs; they are 
comprised of single-pass, transmembrane cadherin proteins that are linked to the actin 
cytoskeleton through the catenin complex.  Although there are a number of different known 
cadherin molecules [81] (each with a varied expression domain), they all share the ability to 
mediate homophilic interactions between cells via their five extracellular (EC) domains [82].  
Intracellularly, the cadherins share the ability to bind to p120 catenin and ?-catenin [82-84].  In 
fact, the cadherin molecule is required to establish the junction and recruit the necessary 
accessory proteins [85]. Historical thought is that ?-catenin is recruited to the cadherin-?-catenin 
complex and this association allows a number of other actin-binding proteins to enter the 
complex, including vinculin, ?-actinin, and formin-1 [86, 87].  It is believed that the activity of 
?-catenin is the source of regulation for actin dynamics at adherens junctions, either by 
suppressing Arp2/3 nucleation of actin or by recruiting formin-1, which nucleates unbranched 
actin cables [88].  Recently it has been shown that ?-catenin can either bind to the adherens 
junction complex or to F-actin, but not both at the same time [89, 90].  It is still not exactly clear 
how actin is anchored to adherens junctions, but there are a few candidates and more research is 
necessary to determine how these links are organized.   
In addition to forming cell contacts to the ECM or other cells, the distribution of adhesion 
structures helps to establish cell polarity. Tight junctions define the boundary between the apical 
domain and the lateral side of the cell, while adherens junctions mark the apico-basal boundary.  
Polarity is an important feature of cells that helps to drive many physiological processes, such as 
regulating nutrient absorption and water balance in intestinal epithelia, asymmetric cell division, 
and morphogenetic movements (discussed in section 1.3).   
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Figure 2: Model of Cell Adhesion Structures 
A. The tight junction (TJ) is the apical most adhesion structure in a polarized cell.  TJs are comprised of a 
transmembrane adhesion protein, such as claudin, occludin, or JAM (blue), and a number of intracellular 
components.  The conserved Crumbs-Pals1-PatJ (yellow) and Par3-Par6-aPKC (red) complexes along 
with other scaffolding proteins like ZO-1 (orange) help to link the entire junction to the actin 
cytoskeleton.  B.  Adherens junctions utilize the cadherin family of transmembrane proteins (black) to 
facilitate adhesion.  p120 and ?-catenin (light blue) bind directly to the cytoplasmic cadherin domain and 
together they recruit a number of actin binding proteins (pink), like ?-actinin, to the complex.  C.  Focal 
adhesion complexes provide a means of linking the cell to the extracellular matrix.  Integrins (yellow) are 
transmembrane proteins that bind to the ECM and a number of signaling and actin-binding proteins (blue 
and pink).  These proteins provide a direct like to the actin cytoskeleton (vinculin) and cause rapid 
cytoskeletal remodeling through various signaling cascades (FAK, RhoGEF).  These models are based on 
those in [72] [82] [91]. 
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1.2.2 Vesicular Transport 
Vesicular transport is yet another cellular process that has actin filaments as a core necessity.  
The random diffusion of vesicles would be extremely slow in the crowded environment of the 
cytoplasm and most often vesicles must be specifically delivered to a particular destination, 
therefore requiring the aid of molecular motors to assist in transport.  Actin filaments can 
function as a track for vesicles to be transported along or as a scaffold to help arrange the 
receptor-mediated endocytic machinery [92, 93].  Myosin motors are the machinery that utilizes 
actin as a scaffold.  There are 18 known classes of myosin molecules in the myosin superfamily, 
each of which is characterized by a globular motor domain (heavy chain), that binds to actin 
filaments in an ATP-dependent manner, and an ?-helical rod domain [94].  The ?-helical region 
facilitates oligomerization forming the coiled-coil, which tethers multiple motor domains 
together allowing processive movement along an actin filament.  The coiled-coil domain is also 
able to bind to an assortment of cargo, thereby creating an intracellular transport mechanism 
[95].  The binding of intracellular vesicles (or organelles) to the actomyosin machinery and the 
ability of myosin to ‘walk’ along the filament could be facilitated by the host of GTPases that are 
present in the endocytic machinery [96].  It is still somewhat speculative as to how myosin 
proteins play a role in endocytosis, but regulation of actin dynamics or myosin through the Rho-
ROCK pathway is one plausible mechanism [97]. 
It should be clear at this point that while actin plays a key role in many specific 
processes, it often coordinates many of the mechanisms described above into an intricate cellular 
response.  For example, cell migration is a combination of dendritic branching of actin filaments 
coupled with changes in focal adhesion contacts with the ECM, changes that are orchestrated 
through ‘outside-in’ signaling.  Cytokinesis is the elegant combination of actin filaments being 
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anchored to membrane components around the cytokinetic furrow while being constricted by 
myosin motors (myosin II), much like cinching a belt [15].  Signal transduction through actin-
based adhesion structures can, in turn, reorganize the cytoskeleton to enable the cell to detach 
from its neighbors for migration or more impressively allow the cell to function as part of a 
unified whole.  The combination of actin-based processes among cells in a given field, create 
some of the most phenomenal events in biology. 
1.3 ACTIN AND DEVELOPMENT 
One of most fundamental questions in biology is how complex multicellular organisms are 
created from a single diploid cell.  The highly regulated and conserved signaling mechanisms 
that create ‘microenvironments’ for different populations of cells must be interpreted by those 
cells to elicit polarized cell divisions, to change the intracellular architecture, or to orchestrate 
gross morphological changes within a field of cells.  These phenomena are observed in early 
embryonic development of many organisms ranging from Drosophila to mice. 
The cell adhesion structures described earlier can function to direct a group of individual 
cells into a unified multi-cellular structure that can act as a single unit.  Tight and adherens 
junctions physically link cells together, and in doing so they provide a means of coordinating the 
cytoskeletons of all the cells involved.  The adhesion structures are modular complexes that 
require specific signals to elicit a cellular response.  It is the regulated linkage of these structures 
to the actomyosin network that enables the large morphogenetic movements required for 
embryonic development.    
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1.3.1 Convergent-Extension 
Convergent-extension (CE) is one such morphological movement during gastrulation, which is 
under the control of  ‘tissue polarity’, that is now better known as planar cell polarity (PCP) (see 
section 1.3.2).  CE refers to the process of a field of cells narrowing or converging towards its 
midline and then extending perpendicular to the direction of narrowing [98].  Imagine a square 
containing 16 cells and has a left (L)-right (R) axis and an anterior (A)-posterior (P) axis (Fig 
3A).  In order to make the square into a rectangle, the 4 cells lining the L border and those lining 
the R boarder need to converge towards the A-P axis and intercalate between the middle two 
rows of cells (Fig 3B).  The intercalation of the L and R cells forces the A-P axis to expand, 
because now instead of four rows of four cells there are two rows of eight cells!  This is the idea 
behind many of the morphological movements in metazoan development and is a well-
documented process [99].  Of course, a developing embryo is a three-dimensional structure and 
much larger changes can be envisioned if the previous example of a square is changed to a cube 
that now contains 64 cells instead of 16 (Fig 3B).  The underlying mesenchymal cells (red 
outline) generate a much larger force effect when they intercalate into a pre-existing ectodermal 
sheet (due to the necessary rearrangements that must occur in the ectoderm), a process that must 
be driven by the force generating system of the contractile actomyosin machinery.   
Two models have been proposed to help explain the movements of CE: The cell-cell 
traction model and the cell-matrix model.  In either case, the model is based on a stiff 
cytoskeletal network that pulls the cells across each other (traction) or across the ECM (matrix).  
There is evidence for both models and perhaps each has a role in facilitating morphogenesis.  
While CE is an incredible display of very synchronized, deliberate cell movements, there must 
have been a pre-existing mechanism that initially patterned the field of cells.  It has recently been 
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established that the PCP pathway is the necessary signaling pathway that conducts groups of 
cells into functioning as a single unit. 
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       Figure 3: Mechanism of Convergent-Extension 
 
Figure 3: Model of Convergent-Extension 
A.  A sheet of cells (represented by ovals) will extend along the U-D axis when the outermost cells 
intercalate towards the interior of the sheet, along the L-R axis.  Colored ovals represent the exterior most 
cells.  B.  In a three-dimensional system, the cells will converge and intercalate along the L-R axis AND 
the U-D axis.  This will cause the structure to extend along the A-P axis.  Only half of the extended sheet 
is depicted, with a few of the mesenchymal cells intercalated.  Black outlined cubes represent ectodermal 
cells, while red outlined cubes represent the underlying mesenchyme. A-P = anterior-posterior.  D-V= 
dorsal-ventral.  L-R= left-right.  Model based on [99]. 
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1.3.2 Planar Cell Polarity 
Although the idea of tissue polarity was first described in 1982 [100], it has only been in the last 
10 years that the PCP pathway has begun to be understood [101, 102].  Planar polarity is 
probably best defined as any process that affects cell polarity within an epithelial plane and 
involves one or more of the core PCP genes [103].  Most of the early description of PCP resulted 
from research examining the hairs and bristles on Drosophila.  As is true for most signaling 
pathways, much of the core machinery is conserved from flies to humans.  In fact, it is the non-
canonical Wnt signaling pathway that is responsible for PCP.  The canonical Wnt (wingless in 
Drosophila) signaling pathway is used to create a transcriptionally active pool of ?-catenin 
through the repression of GSK-3?.  When active, GSK-3? targets ?-catenin for degradation, 
however when Wnt binds to its receptor Frizzled (Fz), the intracellular signaling molecule 
disheveled/Disheveled (dsh/Dvl) is phosphorylated and can then inhibit GSK-3?.  The increased 
levels of ?-catenin are then able to translocate to the nucleus, and form complexes with the 
TCF/LEF family to regulate transcription [104].   
The non-canonical Wnt pathway uses the same basic proteins (a Wnt signal that binds to 
the Fz receptor and activates DVL) to elicit a much different response.  However, in non-
canonical Wnt signaling the pathway splits at DVL and a different cascade is activated [105].  In 
this pathway there are a number of ‘core PCP’ components involved that are not part of the 
canonical pathway and are conserved from Drosophila to humans.  In addition to the canonical 
Wnt, Fz, and Dvl, the other non-canonical proteins include transmembrane receptors, like 
Strabismus and Flamingo, intracellular proteins, such as prickle and the formin homology 
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domain protein Daam1, and other downstream signaling molecules, including the Rho GTPase 
family and the C-jun N-terminal kinase (JNK) [105].  Outside of these core proteins, there are 
many non-conserved molecules that either function solely in Drosophila or specifically in 
mammals.  
As previously described, the Rho family of GTPases is commonly used to elicit changes 
in cytoskeletal architecture.  The PCP pathway uses the non-canonical Wnt signaling cascade to 
activate the Rho pathway to induce convergent-extension [98].  In this cascade of signals, Dsh 
interacts with Daam1 (Dishevelled-associated activator of morphogenesis), which is also able to 
simultaneously bind to and activate Rho [106].  As described earlier, Rho can activate ROCK, 
which can then affect downstream actin rearrangements.  These actin rearrangements could then 
possibly affect the convergence of cells by contraction of F-actin elements along the medio-
lateral axis and conversely, promote elongation by extending lamellipodia in the anterior-
posterior directions. 
This above list of PCP genes is by no means all-inclusive (for reviews see [103, 107]), 
but it serves to illustrate that the PCP pathway can also regulate cytoskeletal dynamics through 
the intracellular effectors of the pathway.  The regulation of the PCP pathway is critical for 
normal development and defects in any component can lead to severe developmental defects.   
1.3.3 Neural Tube closure 
One morphogenetic process that depends on the PCP pathway and CE movements is neural tube 
closure.  Neural tube closure (NTC) is a complex morphogenetic event that requires the function 
of over 190 genes, all of which exhibit a neural tube defect (NTD) phenotype when mutated in 
mice [108].  Impressively, this number only includes the genes that function after initial 
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patterning of the neural ectoderm is completed [109].  In fact, this complicated morphogenesis is 
so sensitive to even minor perturbations that NTDs affect nearly 1/1000 births.  The neural 
ectoderm begins as a flat sheet of epithelial cells, also called the neural plate, which is formed 
through CE movements governed by the PCP genes Van Gogh like 2 (vghl2), Celsr, Scribble, 
and dishevelled.  Mutations in those genes (loop-tail, crash, circletail, and Dvl-1;Dvl-2 
respectively [110-113]) are associated with a specific birth defect called craniorachischisis which 
is caused by the failure of NTC to originate at the hindbrain/cervical boundary.  It is thought that 
the NTDs caused by these mutations are actually the result of a slightly deformed neural plate.  If 
the neural plate is properly patterned, NTC results from the bending of the neural ectoderm, the 
subsequent elevation and further bending of the neural folds, and finally fusion at the dorsal 
midline [114].  Fusion of the neural folds is initiated at a few specific locations along the neural 
axis and proceeds in a zipper-like fashion in both the anterior and posterior directions.  NTDs in 
the anterior most region of a mouse embryo are known as anencephaly or exencephaly, whereas 
NTDs in the posterior of the embryo are more commonly known as spina bifida.   
It can be imagined that this large-scale morphogenesis must be well coordinated and 
depends on the function of cytoskeletal components to provide the necessary tension and force to 
facilitate such a drastic rearrangement.  Indeed, mutations in various proteins known to regulate 
cytoskeletal dynamics have been shown to result in NTDs.  Among these are vinculin (focal 
adhesion associated protein) [115], MARCKS (PKC target and F-actin cross-linking protein) 
[116], p190 (RhoGAP) [117], Mena/profilin double mutants [118], and the non-receptor tyrosine 
kinases Abl and Arg [119] (for a review of all the known genes see [108]).  Shroom3 is another 
actin-regulatory protein that is required for NTC [120] and will be discussed in greater detail in 
the next section.  In addition, treatment of embryos with cytochalaisin D (a toxin that causes F-
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actin to depolymerize [121]) also leads to similar NTDs [122, 123].  Interestingly, all of these 
mutations affect cranial NTC, but spinal NTC remains relatively unaffected, indicating a 
differential requirement for the contractile actomyosin belt that is positioned at the apical surface 
of the neuralepithelial cells.   
1.3.4 Actin and Myosin II in Other Developmental Processes 
A number of other mechanisms depend on the activities of a fully functional and tightly 
regulated actomyosin network.  Eyelid closure, a process akin to NTC, in mice requires the 
contractile ability of the actomyosin network [124, 125].  In this example, the activity of ROCK-
I and ROCK II are required to stimulate myosin light chain (MLC) phosphorylation, which in 
turn facilitates the cross-linking of actin filaments in the eye epithelium.  The activated myosin 
then triggers the assembly of actomyosin bundles.  These bundles then provide the tension 
necessary to drive eyelid closure prior to birth (the mutant phenotype is referred to as ‘eyes open 
at birth’ or EOB).  The signaling pathway leading up to eyelid closure is initiated extracellularly 
by epidermal growth factor (EGF) binding to the EGF receptor (EGFR) [124, 126-128].  The 
EGF stimulus actually provides a positive feedback loop for the formation of actomyosin cables.  
Interestingly, but not too surprisingly, in the ROCK-I deficient mice, a similar defect is observed 
during the umbilical ring closure. 
As indicated above, the development of the embryonic nervous system is incredibly 
complex and NTC is by no means the only process governing neural development.  Neuronal 
cells have to migrate to the correct locations within the developing organism, create the 
appropriate cell junctions, and ultimately be able to release neurotransmitters into the synaptic 
junctions.  Of course, all of these processes require actin and myosin.  Cell migration is a process 
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that involves many of the components discussed elsewhere (see section 1.1), however a recent 
study in mice has placed this mechanism at the heart of a neural development.  In this study, the 
n-cofilin knockout mouse displays neural tube closure defects, but it also exhibits a specific 
defect in neural crest cell (NCC) migration [129].  NCCs from these mice not only fail to migrate 
from cultured explants, but they lack any F-actin based structures.  Axon guidance also depends 
intimately on an actomyosin network.  Migrating axons are constantly encountering guidance 
cues that promote migration or retraction (repulsive cues).  These cues are often mediated 
through the Rho GTPases to affect cytoskeletal changes.  As an example, the guidance cue 
semaphorin-3A triggers the RhoA-ROCK pathway to activate myosin II and, in this case, create 
a unique F-actin bundle.  This bundle provides the scaffolding for the myosin-facilitated 
retraction [130]. 
As described above, the ability of actin to elicit changes within a cell or a field of cells in 
response to external signals is essential for many biological processes to occur normally.  The 
regulation of actin is at the heart of its function and thus it makes sense that there are hundreds of 
proteins that affect actin dynamics or function in some fashion.  Often times, the proteins that 
can affect actin dynamics are classified into families that represent a conserved mechanism or 
some conserved homology specifically among those in the group.  The next section will describe 
in detail a family of proteins that are involved in regulating the actin cytoskeleton with mutant 
phenotypes that affect various aspects of neural development. 
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1.4 THE SHROOM FAMILY OF PROTEINS 
The Shroom (Shrm) family of proteins is a small family of actin binding proteins that are able to 
induce cytoskeletal changes and thereby influence cellular function.  There are four Shrm family 
members in vertebrates, and these were originally identified as Apx [131], Apxl [132], Shroom 
[120], and KIAA1202 [133] and have recently been renamed Shrm1, Shrm2, Shrm3, and Shrm4 
respectively [134].  The family is defined by the conservation of at least 2 of 3 domains: an N-
terminal PDZ domain, a centrally located Apxl/Shrm Domain (ASD) 1 domain, and a C-terminal 
ASD2 domain (Fig. 4A).  PDZ domains are well known for their ability to serve as protein-
protein interaction motifs, however the binding partners for the PDZ domains of the Shroom 
family have not yet been identified (Fig 4B).  The ASD1 domain of Shrm2 and Shrm3 has been 
experimentally shown to bind directly to actin and is able to target the proteins to the proper sub-
cellular localization [135].  However, this motif displays a differential ability to bundle actin.  
The ASD1 element from Shrm3 is able to facilitate the bundling of actin filaments, whereas the 
ASD1 element from Shrm2 is not competent to do so [135].  This difference could perhaps 
reside in the sequence surrounding the ASD1 domain.  The ASD2 domain is the most conserved 
domain, as all Shrm family members have one, and has quite elegantly been shown to facilitate 
an actomyosin-based constriction event [135, 136] (Fig. 4C).  
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Figure 4: The Shroom family of Proteins 
A.  Domain map of the vertebrate Shroom proteins.  The PDZ domains (light gray oval) and 
ApxL/Shroom/Domain 1 motifs (ASD1, black oval) are conserved in most of the Shrm family members.  
The ASD2 domain (dark gray oval) is conserved in all known family members.  B. Sequence alignment 
of the conserved PDZ domains from Shrm3, Shrm2, and hShrm4.  Note the number of conserved G-L-G-
F residues (hallmark of PDZ domains).  C. Sequence alignment of the conserved ASD2 domains.  Both 
vertebrate and invertebrate sequences are compared. 
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1.4.1 Sub-cellular Function of Shroom 
Shrm3 is able to target to the apical surface of epithelial cells and cause the apical surface to 
constrict relative to the basal surface (Fig 5A) [136].   Expression of a Shrm3 protein construct 
lacking the ASD1 domain does not cause constrictions when transiently transfected into MDCK 
cells.  This is most likely due to improper targeting.  Likewise, the expression of a Shrm3 
construct that lacks the ASD2 domain fails to cause constrictions in tissue culture cells even 
though it is apically localized.  Additionally, in these experiments it is shown that Shrm3 directs 
the apical positioning of F-actin and non-muscle myosin II (NMMII) creating a contractile apical 
actin ‘belt’ (Fig 5B) [136].  The ability of Shrm3 to induce constrictions depends on the activity 
of ROCK (but not RhoA).  It is the ability of Shrm3 to localize to the apical surface and facilitate 
actomyosin-based constrictions that allows it to govern the morphogenesis of the neural tube 
from the neural plate (discussed below).   
When ectopically expressed in MDCK cells, neither Shrm2 nor Shrm4 are able to induce 
a constriction event.  In fact, neither of these proteins is targeted to the apical surface.  However, 
chimeric proteins containing the localization motif (ASD1) of Shrm3 and the ASD2 domain of 
either Shrm2 or Shrm4 are able to trigger an apical constriction event in MDCK cells.  These 
data show that the function of the ASD2 domain is conserved among the Shrm protein family 
members, and it is the differential expression and sub-cellular localization that causes them to 
assume different roles [135].  Interestingly, some Shrm proteins have been shown to affect other 
cytoskeletal components in addition to actin.  It has recently been shown that Shrm1, Shrm2, and 
Shrm3 can regulate the distribution of ?-tubulin in developing eye epithelial cells [137, 138], 
however the mechanism (and purpose) of this event is still ill-defined.  In fact, neither Shrm2 nor 
Shrm3 is able to recapitulate this event in MDCK cells (Hildebrand, unpublished data). 
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Figure 5: Sub-Cellular Function of Shrm3 
A.  Shrm3 is able to effect cell shape change in epithelial cells.  The expression of Shrm3 causes the 
apically located actin (red lines) to constrict, forcing the entire apical surface to constrict.  B.  Shrm3 
elicits acpical constriction through myosin II, by way of the ROCK pathway.  Shrm3 binds to apical actin 
via its ASD1 motif (blue).  Additionally, Shrm3 recruits myosin II through the function of the ASD2 
domain (red).  However, the details of this recruitment are unclear.  The constriction event is dependent 
upon ROCK signaling.  AJC = apical junctional complex. Figure based on that from [136]. 
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1.4.2 Shroom is Evolutionarily Conserved 
The Shrm family is conserved across many species with orthologs found in organisms ranging 
from Drosophila to Homo sapiens.  As described above, many vertebrates have most, if not all, 
of the family members, while the invertebrates seem to have one Shrm related ortholog (Fig. 
4C).  The Shrm related proteins found in invertebrates all seem to contain a conserved ASD2 
domain, and a few have a conserved PDZ domain (Ciona and sea urchin) with little homology to 
any Shrm protein outside of these domains.  The Drosophila Shroom (dmShrm) protein cannot 
induce apical constriction in transiently transfected MDCK cells.  However, when the dmShrm 
ASD2 domain is targeted to the apical surface (in the same type of chimeric experiments 
described above), it is able to facilitate an apical constriction event.  The developmental role of 
the invertebrate Shrm orthologs is currently under investigation, but these proteins could provide 
great insight into evolutionarily conserved mechanisms of development. 
When comparing all of the Shrm family proteins, it is quite apparent that they fall into 
two categories: Those with an ASD1 domain and those without one.  This makes for quite an 
interesting observation, as the only vertebrate Shrm protein that lacks the ASD1 domain is 
Shrm4.  Shrm4 could perhaps be the most ‘ancestral’ of the Shrm proteins since its protein 
structure most closely resembles that of the invertebrate Shrm ortholog.  In fact, a gene 
duplication of the early Shrm protein most likely resulted in the dichotomy, giving rise to 
versions found in vertebrates, those without ASD1 (Shrm4) and those with (Shrm2 and Shrm3) 
[135].  Outside of the conservation of the ASD2 domain, little is known about the invertebrate 
Shrm orthologs.  However, the vertebrate Shrm proteins have been well described in the 
literature, and most play key roles in specific developments processes. 
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1.4.3 Developmental Role of the Shroom Family of Proteins 
As described above, the actin cytoskeleton plays a critical role in many developmental processes.  
Proper regulation of cytoskeletal dynamics (both spatially and temporally) is essential for the 
normal development of an organism as well as the homeostasis of adult tissues.  Many of the 
vertebrate homologs of the Shrm proteins have been implicated in regulating specific aspects of 
development.  Shrm3 is required for proper neural tube closure in mice, Shrm2 is required for 
normal retinal development, and Shrm4 has been implicated in X-linked mental retardation. 
1.4.3.1 Shroom3 and NTC 
As described previously, NTC is a complex morphogenetic process that intimately depends on 
actin dynamics to complete its formation.  Shrm3 deficient mice fail to close their neural tubes 
and display various open neural tube phenotypes such as spina bifida, anencephaly, and 
exencephaly [120].  In Xenopus, xShrm3 is required for NTC since morpholino knockdowns and 
expression of a dominant-negative xShrm3 cause NTDs [139].  Shrm3 is localized to the apical 
junctional complex (TJs) of the neuralepithelia during neurulation and is able to direct 
actomyosin-based apical constrictions (see above).  These two mechanistic details (expression 
domain and cellular function) along with the open neural tube phenotype, show that Shrm3 plays 
a direct role in this crucial morphogenesis and is absolutely required ensure it is properly 
completed. 
1.4.3.2 Shroom2 and Eye Development 
The retinal pigment epithelium (RPE) is a layer of epithelial cells that is required to prevent the 
scattering of light within the retina [140].  In order to function normally, this layer of cells 
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requires pigmentation by melanosomes during retinal development.  Many genes have been 
identified that regulate both the biogenesis of melanosomes as well as their proper localization, 
including myosin VIIa [141, 142].  Mutations in the genes encoding these proteins have been 
implicated in many human disorders affecting retinal development.  xShrm2 has recently been 
shown to be required for RPE development in Xenopus [137].  Morpholino knock-down of 
xShrm2 results in reduced retinal pigmentation due to aberrant lamination, abnormal RPE 
structure, and defects in the position and maturation of melanosomes within the RPE.  
Interestingly, hShrm2 is located on the X chromosome in a region that is associated with Ocular 
Albanism (OA1), a disease state that is characterized, in part, by hypopigmentation and defective 
melanosomes [143].  No direct evidence has been discovered that implicates hSHROOM2 in 
OA1, but the fact that the gene covers over 70% of the OA1 critical region makes it an 
interesting candidate.  It is important to remember that Shrm2 expression in MDCK cells is not 
sufficient on its own to drive apical constrictions and similarly, xShrm2 expressing cells do not 
exhibit apical constrictions in developing Xenopus embryos.  So unlike Shrm3, where the ability 
to direct apical constrictions is at the heart of its function, Shrm2 most likely elicits its function 
through a different mechanism, perhaps utilizing ?-tubulin to regulate melanosome localization.  
1.4.4 Shroom4 : XLMR and Initial Characterization 
While gross morphological aberrations can cause severe and often lethal birth defects, more 
subtle types of mutations can lead to non-lethal, yet debilitating maladies. One consequence of 
irregular neural development is mental retardation, which is reported to affect 1-3% of the 
world’s population [144].  Of these cases, more than 10% have been attributed to mutations in 
genes on the X chromosome, also referred to as X-linked mental retardation (XLMR).  The 
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mutations leading to XLMR fall into quite a few gene categories, and it is not surprising that a 
number of these are gene products that affect actin dynamics at some level, including the Rho 
effectors ARHGEF6, ARHGEF9, FGD1, OPHN1, and PAK3, and actin binding proteins FLNA 
(filamin) [145].   
Recently it has been reported that mutations in hShrm4 (SHROOM4) are also associated 
with XLMR [133].  In this study, two unrelated patients are carriers for mutations that result in 
XLMR, while 6 other families harbor innocuous polymorphisms.  The two XLMR mutants are a 
silent E474E (A>G) mutation and a missense S1089L (C>T) mutation.  hShrm4  cDNA (6,029 
bp) was first isolated from a screen from a large-insert adult brain library [146].  Five different 
isoforms were isolated, one of which corresponded to the cDNA and encoded a 1498 AA 
protein.  hShrm4 consists of 10 exons, with the majority of the coding region found in exon 4.  
The intron-exon structure closely resembles that of Shrm3, with exons one and two separated by 
over 117,000 bp and exons 2 and 3 separated by about 57,000 bp.  hShrm4 has the conserved N-
terminal PDZ domain and C-terminal ASD2 domain and a putative PDZ binding site as the last 3 
AA.  In addition, hShrm4 contains a potential EVH1 binding site (FPPPP) and a large stretch of 
glutamine and glutamic acid residues.  Expression analysis of the RNA by Northern blot reveals 
ubiquitous, but seemingly differential, expression of hShrm4 in adult tissues (including 8 sub-
regions of the brain).   
Analysis of mShrm4 (the basis of this dissertation) similarly revealed ubiquitous 
expression of the RNA in all adult tissues examined as well as embryonic expression beginning 
at E8.5 and persisting throughout adulthood.  The disease causing mutations in hShrm4 lie in a 
region that is roughly 80% identical to mShrm4 and rShrm4, but the actual AA change is in a 
non-conserved serine residue (proline in both mouse and rat).  Subcellular localization studies of 
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hShrm4 show that it is coincident with actin and collapses with actin upon latrunculin B 
treatment.  In all, these studies not only place hShrm4 into the Shrm protein family, but also 
establish yet another neural phenotype associated with a mutation in a Shrm family protein. 
1.5 AIMS OF DISSERTATION RESEARCH 
The importance of the Shroom protein family in neural development is highlighted by the 
discovery and initial characterization of Shrm3.  Since that time, a number of other proteins have 
been identified that share homology with Shrm3 and have been ascribed to the Shroom family of 
proteins.  Shrm1 and Shrm2 had already been somewhat described in the literature, but the less 
similar Shrm4 protein had not.  In fact, at the onset of this work, Shrm4 was little more than an 
uncharacterized ORF discovered in a screen of large-scale cDNAs from an adult human brain 
library.   
The aim of this dissertation research is to identify and clone the murine Shrm4 gene, and 
to characterize the corresponding gene product.  My research on mShrm4 is in agreement with 
what was reported in the original work on hShrm4, but more importantly it has provided greater 
insight to understand how Shrm4 functions and allows for speculation as to how it may play a 
role in XLMR. 
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2.0  MATERIALS AND METHODS 
2.1 MOLECULAR BIOLOGY 
cDNA representing bases 3433-4429 of mShrm4 was isolated from a mouse brain cDNA ? 
library (Stratagene), using the human SHRM4 cDNA as a probe (a gift from the Riken 
Corporation).  PCR was used to amplify bases 3480-4429 with primers (engineered restriction 
enzyme sites underlined): Fwd -? 5’GCCCCgAATtCAGAGGAACAGCC3’ and Rv-? 
5’GGTGCAGTGGCATACTCGAGGTGC3’.  cDNA containing bases 268-3885 were obtained 
from the RIKEN corporation (D430043L16, GenBank  accession BB487710) and bases 861-
3480 were PCR amplified for cloning using the following primer set: Fwd-Riken 
5’GCCTTCCGGCCTCTAGAGCCC3’ and Rv-Riken 5’GGCTGTTCCTCTGaATTcGGGGC3’.  The 
5’ cDNA corresponding to bases 1-861 were PCR amplified from random hexamer primed RNA.  
Primers for PCR were designed based on sequence deposited on Ensembl (ID #: 
ENSMUSG00000068270) with engineered restriction sites for cloning.  Fwd-ATG 
5’GCCCAGatCtAGCCGAGGATGGAGAGC3’ and Rv-ATG 
5’GGGCTCTAGAGGCCGGAAGGC3’.  The three overlapping cDNAs were cloned together into 
pBluescript.  Shrm4 was then sub-cloned into the pCS3mt eukaryotic expression vector.  The 
sequence for mShrm4 has been deposited under GenBank Accession DQ435686. 
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cDNAs encoding fragments of mShrm4 protein were generated using PCR with 
engineered restriction sites, using the following primer sets: 1-522 Fwd-? and Rv 
5’GGAAgAAtTcGCAGAGGGCTGC3’; 522-1180 Fwd 5’GCAGCCCTCTGCgAaTTcTTCC3’ and 
Rv-Riken, 436-966 Fwd 5’GGCAGCAAGGGGATGAATTCGCCAATTGGG3’ and Rv 
5’CCTGGATTTCCAAGAATTCCCAGGTGCC3’.  CS3mt-Shrm4 1180-1475 was generated by 
cloning the insert isolated from the ? library into pCS3mt.  For bacterial expression of Shrm4 
protein, mShrm4 DNA fragments encoding amino acids 350-878 and 1152-1311 were PCR 
amplified and cloned into the pGEX3X expression vector. 
2.2 ANTIBODY PRODUCTION AND PROTEIN EXPRESSION  
Mouse Shrm4-specific sera (UPT114 and UPT155) were generated in rabbits (Cocalico) using an 
antigen consisting of amino acids 1152-1311 (UPT114) and 350-878  (UPT155) fused to GST.  
Antigenic protein was expressed in BL21pLys E. coli and induced with 250 μM IPTG overnight 
at 30
o
C.  Cells were harvested by centrifugation, resuspended in NETN (100 mM NaCl, 1 mM 
EDTA, 20 mM Tris [pH 8.0], 0.05% NP-40) containing a protease inhibitor cocktail, and lysed 
by sonication.  Lysate was cleared by centrifugation and incubated with glutathione-sepharose 
beads at 4
o
C for 2 hours (Amersham).  Sepharose beads were collected by low speed 
centrifugation and washed with ice cold NETN.  GST-mShrm4 fusion proteins were eluted from 
the beads with Elution buffer (20 mM glutathione, 100 mM Tris [pH 8.0], and 120 mM NaCl) 
with protease inhibitors.  Eluted protein was subjected to SDS-PAGE followed by Coomassie 
blue staining to determine concentration and integrity.  Shrm4-specific antibodies were purified 
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from rabbit sera (UPT114 and 155) by chromatography using their respective antigens coupled 
to CNBr-sepharose (Amersham). 
2.3 CELL CULTURE 
Brain endothelial (bEND), C166 yolk sac endothelial, and RAT1 fibroblastic cells (ATCC) were 
maintained in DMEM supplemented with 10% FBS, pen/strep, and L-glutamine at 37
o
C and 5% 
CO2.  HUVEC cells were grown in ECM supplemented with BulletKit (Cambrex) at 37
o
C and 
5% CO2.  Cells grown on gelatin coated glass cover slips were transfected with 1-2 μg of DNA 
using Lipofectamine 2000 according to manufacturer’s recommendations (Invitrogen).  For drug 
treatments, cells were treated with DMSO (vehicle), 2 μM cytochalasin D (CD, Sigma), or 200 
μM blebbistatin (Calbiochem) for 20 or 120 minutes at 37oC, respectively.  Washout 
experiments were completed as described above, except following the drug treatment, the cells 
were washed 3 times in PBS and allowed to recover in DMEM or DMEM + 200 μM blebbistatin 
for 3 hours.  Calyculin A (Calbiochem) was used at 4 nM for 45 minutes and Y-27632 
(Calbiochem) at 20 mM for 1.5 hours.  Nocodazole was used at 33 μM on ice for 30 minutes.   
2.4 WESTERN BLOTTING 
Adult mouse tissue lysates and e10.5 day mouse embryo lysates were generated by 
homogenizing isolated tissues in RIPA buffer (150 mM NaCl, 0.5% sodium deoxycholate, 50 
mM Tris [pH 7.5], 4 mM EDTA, and 1.0% NP-40) on ice with a Tissue Terror/mechanical 
 40 
homogenizer.  Lysate was cleared by centrifugation and supernatant was stored at -80
o
C.  Cells 
ectopically expressing mShrm4 proteins were lysed in RIPA buffer, scraped from the surface of 
the dish, and centrifuged to clear the lysate.  Equal volumes of lysate were loaded and resolved 
on a 10% SDS-PAGE gel, then transferred to a nitrocellulose membrane.  Endogenous and 
exogenous mShrm4 was detected using affinity purified rabbit anti-Shrm4 or mouse anti-myc 
(9E10) antibodies at a dilution of 1:200 in TBST + 4% milk.  Primary antibodies were detected 
using HRP-conjugated secondary goat anti-rabbit or goat anti-mouse antibodies (Amersham) 
diluted 1:2500 in TBST, followed by ECL (Amersham).  
2.5 IMMUNOCYTOCHEMISTRY 
Cells grown on glass cover slips were washed three times with phosphate buffered saline (PBS) 
and fixed with either -20
o
C methanol for 5 minutes or 4% paraformaldehyde (PFA) in PBS for 
15 minutes at room temperature.  PFA fixed cells were permeablized for 5 minutes in PBS + 
0.2% Triton-X 100.  Cells were stained with primary antibodies diluted in PBS + 0.1% Tween 20 
(PBT) supplemented with 1% goat serum (Jackson Labs) for one hour at room temperature.  The 
following antibodies were used: rabbit anti-mShrm4 (1:200), mouse anti-non-muscle myosin II 
(CMII 23, Developmental Studies Hybridoma bank), rabbit anti-non-muscle myosin II-B 
(Covance, 1:200), rat anti-PECAM (BD Pharmingen, 1:400), mouse anti-caveolin (Transduction 
Laboratories, 1:200), mouse anti-Tubulin (a gift from Dr. Charles Walsh, University of 
Pittsburgh), mouse anti-giantin (a gift from Dr. Adam Linstedt, Carnegie Mellon University), 
and mouse anti-rab5 and mouse anti-rab7 (a gift from Dr. Kirill Kiselyov, University of 
Pittsburgh).  Following primary antibody incubation, cells were washed three times in PBT and 
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stained for 1 hour with fluorescently labeled secondary antibodies (Molecular Probes) diluted 
1:400 in PBT.  Secondary antibodies were either Alexa-488 or Alexa-568 conjugated to goat 
anti-rabbit, goat anti-mouse, or goat anti-rat IgG.  Actin was detected using either TRITC or 
Alexa-633 conjugated Phalloidin (Sigma and Molecular Probes, respectively).  Cells were then 
washed as above and mounted on microscope slides with Vectashield (Vector Labs). 
 For staining tissue sections, embryos or adult tissues were isolated and fixed in 4% PFA 
for 1-3 hours, depending on the size of tissue, at 4
o
C.  Samples were then washed extensively in 
cold PBS, equilibrated in 30% sucrose overnight at 4
o
C, embedded in OCT compound, and 
stored at -80
o
C.  Samples were cut into 10-12 μM sections on a Leica cryostat at -20oC and 
placed onto glass microscope slides.  Sections were rehydrated in PBS for 5 minutes prior to use, 
incubated in blocking buffer (PBT + 1% goat serum) and stained overnight at 4
o
C with primary 
antibodies diluted in blocking buffer.  Sections were washed in PBT for 15 minutes at room 
temperature, incubated with secondary antibodies and/or TRITC-phalloidin for 2 hours, washed, 
and mounted using Vectashield.  Images were acquired on a Biorad Radiance 2000 Laser 
Scanning Confocal System mounted on a Nikon E800 microscope (40X oil objective), using 
LaserSharp 2000 software.  Adobe Photoshop software was used to process images. 
2.6 ACTIN CO-SEDIMENTATION ASSAY 
GST-Shrm4 fusion proteins consisting of amino acids 436-966 and 436-1180 were prepared as 
described above, with the exception that cells were lysed using a French press.  F-actin (0.2 μM, 
10-20 μm filaments) was prepared according to manufacturer’s recommendations 
(Cytoskeleton).  Purified GST-Shrm4 and GST alone (control) were pre-cleared at 100,000 x g.  
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The control (GST-Shrm4, GST, GST + actin, and actin alone) and experimental (GST-Shrm4 + 
actin) samples were incubated at room temperature for two hours in F-actin buffer 
(Cytoskeleton).  The supernatant and pellet fractions were separated at 100,000 x g, resolved by 
SDS-PAGE electrophoresis, and visualized by Coomassie blue staining.  For bundling assays, 
samples were prepared as above, except the separation occurred at 10,000g.  In order to 
fluorescently label F-actin bundles, 30 μL of the sample (before centrifugation) was incubated 
with 1 μL of TRITC-phalloidin for 1 hr and placed directly on a glass slide.  Images were 
acquired as described above. 
2.7 WHOLE MOUNT IN SITU HYBRIDIZATION 
Zebrafish embryos were generously provided by Dr. Beth Roman, University of Pittsburgh.  
zShrm4 cDNA was cloned by PCR from a 36 hpf cDNA library (M. Tsang, U. of Pittsburgh), 
using primers designed from the zebrafish Shrm4 sequence on Ensembl.org [147].  The forward 
primer: 5’CCAGCGGTCGTTTAGGTCGATCGGATGAC3’ and the reverse primer: 
5’CTGCAGTACAGGATCCTTTTGGTCCC3’ were used to amplify bases 2624 to 5469 (end) 
of zShrm4.  This PCR product was digested with SacI and BamHI to generate a fragment of 
about 600 bp and cloned into pBluescript (Stratagene).  The plasmid was linearized with SacI for 
riboprobe synthesis.  Digoxygenin-labeled antisense RNA was transcribed using T7 RNA 
polymerase (Stratagene) and Digoxygenin RNA label mix (Roche) according to manufacturer.  
In situs were performed according to [148].  Briefly, embryos were fixed in 4% PFA and 
hybridized overnight with 1:50 dilution of riboprobe in HB4 buffer (50% formamide, 5X SSC, 
5mg/ml yeast RNA, 50 μg/ml herparin, and 0.1% tween).  Following hybridization, embryos 
 43 
were washed with 50% formamide/2X SSC/0.1% Tween, and incubated with the anti-
digoxygenin antibody overnight.  Staining was observed by incubation with NTMT followed by 
NBT/X-phosphate. 
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3.0  CLONING AND INITIAL CHARACTERIZATION OF MURINE SHROOM4 
3.1 INTRODUCTION 
The Shroom family encompasses a relatively small number of proteins that share sequence 
identity in a few conserved domains.  Shrm4 was initially identified as an uncharacterized ORF 
in the human genome that shared homology to the other known Shrm family members.  Since 
nothing was known about Shrm4 functionally, the gene had to be cloned so that a number of 
tools could be created to assist in the elucidation of Shrm4’s function.  The murine Shrm4 gene 
was cloned, because most of the ensuing in vivo types of experiments were to be performed in 
the mouse.  After cloning the mShrm4 cDNA, antibodies were raised against specific non-
conserved regions and were used to investigate the tissue distribution and sub-cellular 
localization of the Shrm4 protein product.  The following sections will describe the cloning of 
mShrm4 and the initial characterization of the protein product. 
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3.2 CLONING OF SHRM4 AND ANTIBODY PRODUCTION 
3.2.1 Cloning of mShrm4 
The mouse Shrm4 gene was cloned using the cDNA corresponding to the ASD2 sequence of 
hShrm4 as a probe for a ?-library screen.  The library we had in our collection did not reveal a 
full-length cDNA clone, so the central portion of the cDNA was obtained from the RIKEN 
Corporation.  The PDZ domain was not present in this clone either (see below), so RT-PCR was 
used to clone the corresponding sequence using the data provided from the Ensembl database 
(www.ensembl.org v.45) [147].  Cloning of mouse shrm4 reveals an open reading frame of 4425 
bp encoding a predicted protein of 1475 amino acids with a predicted molecular mass of 163 kDa 
(Accession number: DQ435686) [149].  Mouse Shrm4 mirrors the organization of the other 
Shrm family proteins [134], such that it contains an N-terminal PDZ domain and a C-terminal 
ASD2 motif, both of which are approximately 60% identical to those of mShrm3 (Fig 6).  Like 
mShrm3 and hShrm4, mShrm4 contains putative binding sites for EVH1 domains (FPPPP) and 
PDZ domains (SNF) [150, 151] (Fig 6A).  In addition, mShrm4 has a leucine zipper heptad 
repeat (bZIP) [152], which is conserved in most of the known ASD2 domains across species 
(Figs 4C and 6A asterisks).  A stretch of glutamines (Q) and glutamic acids (E) 
(QLQQQQQQQQQQQQQQRCEEEEEKEQEEEGEKEE) is located between the EVH1 binding 
site and the ASD2 domain.  This sequence motif is not present in other known Shrm-related 
proteins but is conserved in hShrm4.  While most of the proteins containing polyglutamine 
stretches are regulators of transcription, none of the Shrm proteins have displayed any 
transcriptional activity.  mShrm4 shares 98% and 94% identity to the hShrm4 PDZ and ASD2 
motifs, respectively.  Notably, Shrm4 lacks the central ASD1 (actin-targeting) domain.  Even 
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with the high degree of sequence identity between the mouse and human Shrm4 sequences, the 
region in between the PDZ domain and the ASD2 motif only retains about 70% identity.  Shrm4 
is conserved in a number of non-mammalian vertebrates including Xenopus and Danio (Fig 
7A,B,C).  The full protein sequences for both Danio and Xenopus can be found in Appendix A. 
It is interesting to note that polyglutamine repeats are associated with numerous 
neurodegenerative diseases (NDD) [153], and the number of CAG repeats in Shrm4 falls within 
the “normal” distribution of repeats found in the proteins implicated in NDD.  As previously 
mentioned, this repeat is not conserved across the Shrm family and in fact, only the mammalian 
Shrm4 genes seem to retain this sequence repeat. 
mShrm4 is located on the X-chromosome (like hShrm4 and Shrm2), and its genomic 
organization closely resembles that of hShrm4 and the other Shrm family members (Fig 8A).  
Like the other Shrm genes, there are two exons that encode the PDZ domain, which are roughly 
120 kb apart, and exons 2 and 3 are another 60 kb apart.  Initially, many of the reported Shrm4 
sequences in the database did not include the sequence from the first two exons, indicating that 
the presence/absence of these two exons may represent alternatively spliced isoforms.  This 
makes sense based on what is reported for hShrm4 and for Shrm3.  Exon 4 contains over 2400 
bp of the 4425 bp coding sequence.  It is this exon that will be targeted when creating the Shrm4 
knockout mouse.  In fact, a probe specific for exon 4 was used to isolate a genomic clone of 
mShrm4 from a genomic library.  Since it is necessary to have upstream (5’) and downstream (3’) 
regions of homology for creating a targeting vector, the isolated genomic clone was probed 
either for exon 3 (Fig. 8B) or exon 5 (not shown).   Southern blot analysis revealed that the clone 
was positive for exon 3 sequences, but that is did not include sequence pertaining to exon 5.  The 
prospect of this experiment will be described in greater detail in section 6.4. 
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                                      Figure 6: Cloning of mShrm4 
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Figure 6: Cloning of Murine Shroom4  
A. The mShrm4 encodes a protein of 1475 amino acids that has a number of features that are 
conserved among the Shrm family of proteins, an N-terminal PDZ domain (shaded in yellow) 
and a C-terminal ASD2 motif (shaded in gray).  There is also a putative EVH1 protein-binding 
site (FPPP) (in bold text) and a potential PDZ domain ligand (boxed).  The non-conserved run of 
glutamine (Q) and glutamic acid (E) residues are underlined.  The leucines that make up the 
leucine zipper within the ASD2 domain are marked with an asterisk.  B. The protein map of 
mShrm4, which will be used to designate the protein throughout.  The PDZ domain and the 
ASD2 motif (yellow and gray ovals respectively), the EVH1 site (shaded arrowhead), the Q/E 
run (open arrowhead), and  the C-terminal PDZ binding site (arrow) are all indicated.  The red 
lines mark the regions to which the antibodies were generated. 
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        Figure 7: Alignment of Shmr4 Sequences Conserved Among Species 
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Figure 7: Alignment of Shrm4 Sequences Conserved Among Various Species. 
A.  The relatively non-conserved central domain of Shrm4 does have a short sequence conserved 
in Shrm4 orthologs, which is not conserved in Shrm3.  Sequence corresponds to amino acids 575 
to 622 of the mShrm4 protein.  B.  The PDZ domains of mShrm4 and xShrm4 are more similar 
than zShrm4.  The mShrm3 PDZ is shown for comparison.  C.  The ASD2 domains are also 
conserved among Shrm4 orthologs.  Again, the mShrm3 domain is shown for comparison.  The 
leucine zipper motif is conserved among species as well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51 
     
                               Figure 8: Genomic Organization of mShrm4 
 
Figure 8: Genomic Organization of mShrm4  
A.  The intron/exon boundaries are based on the sequence from Ensembl (www. ensembl.org).  
The exons are numbered and the lines attaching them (above) represent the intervening intronic 
sequence (distances are given for the large introns in kb).  The PDZ and ASD2 coding exons are 
noted as well as the predicted restriction sites for the BglII and Xba I restriction nucleases.  B. 
The represented genomic clone recovered in a genomic library screen with an exon 4 specific 
probe.  The 20 kb insert (lane 1) is flanked by Not I sites in the ?-library cloning vector.  The 
clone was digested with the indicated enzymes and analyzed via Southern blot with a 
radiolabeled probe specific for exon 3. 
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3.2.2 Shrm4 Antibody Production 
Polyclonal antibodies were raised in rabbits against the protein product generated from the 
mShrm4 cDNA.  Two different constructs were used for expressing portions of the mShrm4 
protein that are not conserved among the Shrm family (Fig. 6B, red lines). The N-terminal 
antiserum was raised against amino acids 350-878 and the C-terminal antisera was raised against 
amino acids 1152-1311. The specific antibodies were affinity-purified and both recognize a band 
of about 200 kD from HEK293 cells transiently transfected with a cDNA encoding full-length 
mShrm4.  This is much larger than the predicted molecular mass of 163 kD, however all the 
Shrm family proteins migrate much slower in an SDS-PAGE gel than would be predicted.  This 
is possibly an indication of post-translational modifications, such as phosphorylation, but it is not 
yet known what causes this large discrepancy.   
In order to better characterize the specificity of the antibodies, all of the Shrm4 
expression constructs contain an N-terminal fusion to a 6X myc-tag which is recognized by the 
9E10 anti-myc monoclonal antibody (data not shown).  The N-terminal mShrm4 antibody 
recognizes constructs expressing amino acids 1-522 and 522-1180 of Shrm4, but not amino acids 
1180-1475.  Conversely, the C-terminal antibody recognizes the 1180-1475 construct, but neither 
the 1-522 nor the 522-1180 construct (Fig. 9A, B).  In cell culture, HEK293 cells were 
transiently transfected with an N-terminally myc-epitope tagged mShrm4 construct and stained 
for mShrm4 expression (Fig. 9C).  The 9E10 and the N-terminal mShrm4 antibodies recognize 
the same protein in the cell, indicating not only that the antibody recognizes mShrm4 in vivo, but 
also that the expression construct is able to produce and express a full-length protein in cell 
culture.  Since the antibodies are able to recognize mShrm4, they were next used to examine the 
endogenous tissue distribution and sub-cellular localization of Shrm4.   
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Figure 9: Analysis of mShrm4 Using Affinity Purified Anti-Shrm4 Antibodies 
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Figure 9: Analysis  of mShrm4 Using Affinity Purified Anti-Shrm4 Antibodies 
A.  The C-terminal affinity purified anti-Shrm4 antibody recognizes Shrm4 protein in lysates from 
transiently transfected HEK293 cells.  The full-length Shrm4 and a construct lacking the PDZ domain 
(dPDZ) migrate around 200 kDa.  A construct consisting of amino acids 1180-1475 is also recognized.  
An untransfected cell lysate was loaded as a control.  B.  Similarly, the N-terminal affinity purified 
antibody also recognizes Shrm4 protein in lysates from transiently transfected HEK293 cells.  The protein 
constructs 1-522 and 522-1180 fall within the antigenic region of the antibody, whereas the 1180-1475 
construct does not.  C.  HEK293 cells were transiently transfected with the full-length mShrm4 construct 
(containing an N-terminal myc epitope tag) and stained to detect  myc (red) and mShrm4 (green).  The N-
terminal anti-mShrm4 and the 9E10 anti-myc primary antibodies were used and detected with Alexa-488 
or Alexa-568 secondary antibodies.   D.  Western Blot of lysates from e12.5 whole embryo and adult 
tissues.  mShrm4 was detected using the C-terminal mShrm4 antibody and a HRP-conjugated secondary.   
For all blots, equal volumes of lysate were loaded onto the gels, resolved by SDS-PAGE, transferred to 
nitrocellulose, probed with the primary Shrm4 antibody, and were detected using an HRP conjugated 
secondary and enhanced chemiluminescence (ECL). 
 
 
3.3 EXPRESSION AND LOCALIZATION OF ENDOGENOUS mSHRM4 
3.3.1 Tissue Distribution of Shrm4 in Embryonic and Adult Tissues 
The distribution of mShrm4 in a number of different tissue types was examined both by Western 
blot (WB) and by immunofluorescence (IF).  All the tissues examined (both embryonic and 
adult) were positive for Shrm4 by WB (Fig. 8D).  These data are in agreement with the 
ubiquitous expression observed for the Shrm4 mRNA [133].  In brain, the Shrm4-specific 
antibodies reproducibly detect a protein with an apparent molecular mass of 90 kDa (Fig. 8D, 
arrow).  It is unclear if this protein species results from alternative RNA splicing, post-
translational modification of full-length Shrm4, or represents an unrelated protein with a shared 
epitope. 
Based on the ubiquitous expression of Shrm4 and the known expression pattern of Shrm2 
and Shrm3 [120, 135, 136], the cellular distribution of Shrm4 within the tissue architecture was 
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examined by IF (Figs. 10 and 11).  Frozen sections from embryonic day (e) 12.5 and e15.5 
mouse embryos and adult mouse tissues were stained to detect Shrm4, along with a number of 
marker proteins.  Shrm4 is expressed in the developing eye epithelium in e15.5 mouse embryos 
(Fig. 10 A and B).  It appears that Shrm4 is expressed at the apical surface in these cells as well 
as along the lateral membrane of these cells (Fig. 10A, arrowhead and arrow respectively).  
However, in single optical sections, it appears that Shrm4 localizes in puncta just basal to the 
apical actin network in these cells (Fig. 10B, box).  This punctate staining is also observed in the 
neural tissue as well (Fig. 10D, box).  In e12.5 mouse embryos, Shrm4 is enriched at the apical 
surfaces of the neural epithelium (Fig. 10C, D arrowhead).  Strikingly, Shrm4 is prominently 
expressed in the developing vasculature of the neural epithelium (Fig. 10D).  Shrm4 is in the 
endothelial cells of the vasculature as it is co-expressed with PECAM.  Similarly, Shrm4 is co-
incident with PECAM in the highly vascularized adult lung (Fig. 11A).  Similar to the 
observations in the embryonic eye and neural tissue, Shrm4 is also enriched at the apical surface 
of the adult kidney tubule epithelium as well (Fig. 11 B, C).  In all tissues observed, Shrm4 co-
localizes with actin (Figs 10A, B and 11B, C and data not shown).  In addition, in kidney 
tubules, Shrm4 is detected in a punctate pattern in the cytoplasm and co-localizes with actin at 
the basal surface of these cells (Fig 11C).   A transverse section through the adult epidermal layer 
reveals that Shrm4 appears only to be expressed in the polarized cell populations of the tissue 
(Fig 11D), as Shrm4 only co-distributes with E-cadherin (Fig 11D, arrows).  It is interesting to 
note that Shrm4 seems to selectively be expressed in polarized endothelial and epithelial cells, as 
indicated by co-incidence with PECAM, ?-catenin, ZO-1, and E-cadherin.  The IF of various 
tissue sections gives an informative, yet incomplete picture of Shrm4 localization.  In order to 
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better understand Shrm4 function, an understanding of the sub-cellular localization of Shrm4 is 
necessary. 
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             Figure 10: mShrm4 Localization in Embryonic Tissue Sections 
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Figure 10: Shrm4 Localization in Embryonic Tissue Sections. 
Cryo-sections of e15.5 (A and B) or e12.5 (C and D) mouse embryos were stained to examine Shrm4 
localization in the developing embryo.  In the developing eye epithelium, (A and B), Shrm4 is enriched at 
the apical-basal boundary (arrowheads).  The boxed region in B shows the punctate localization at the 
basal surface of these epithelial cells (compare the actin staining (red) at the right of the boxed area to the 
left of the boxed area).  Panel B is a single optical section from the Z-series used to make Panel A.  In the 
head region of an e12.5 mouse embryo (C and D), Shrm4 (green) localizes to the apical surface of the 
neural epithelium (C and D, arrowheads).  ?-catenin (C, red) marks the AJ in the neuroepithelial cell.  
Shrm 4 is also expressed in the endothelial cells of the vasculature as indicated by PECAM (D, red) 
expression. 
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        Figure 11: mShrm4 Localization in Adult Tissue Sections 
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Figure 11: Shrm4 Localization in Adult Tissue Sections 
Cryo-sections of adult tissues were used to examine Shrm4 localization in the adult lung (A), kidney (B 
and C) and epidermal layer (D).   Shrm4 (green) is expressed in the endothelial population of the lung 
vasculature (PECAM, red) (A, arrow).  Shrm4 is also expressed at the apical surfaces lung epithelial cells 
(A, arrowhead).  In the adult kidney (B and C), Shrm4 (green) is expressed in the apical and basal 
surfaces of the epithelium comprising the kidney tubules.  Shrm4 is largely coincident with actin (red). 
Panel C shows a higher magnification of the Shrm4 distribution in kidney tubules.  In the adult epidermal 
layer (D), Shrm4 (green) is expressed in a number of structures comprised of epithelial cells (arrows) 
including the outer most layer of the skin (arrowhead) as indicated by the co-distribution with E-cadherin 
(red).  The apical-basal architecture (A-B) of the whole tissue is noted (double-ended arrow).   
 
 
3.3.2 Sub-Cellular Localization of Endogenous Shrm4  
To more closely examine the sub-cellular distribution of Shrm4, primary mouse cells were 
cultured and stained to detect Shrm4 and F-actin.  In primary mesenchymal cells, Shrm4 is 
typically detected in a pattern that is reminiscent of extended vesicles or short, dense filaments 
(Fig 12A-C).  In addition, Shrm4 is observed in patterns that are reminiscent of focal adhesions 
(Fig 12D) as well as membrane localization (Fig 12E).  Since the filamentous pattern is the most 
commonly observed, that will be the focus of the remainder of this research.  These structures 
can be found in either the cytoplasm or in close proximity to the plasma membrane (compare Fig 
12A to 12C).  Co-staining to detect Shrm4 and F-actin indicates that these Shrm4-containing 
structures are typically co-incident with a distinct compartment of the actin cytoskeleton (Fig 
12F).  This actin population is not particularly obvious and is only apparent in light of the 
localization of Shrm4.  The Shrm4-associated actin is often diffuse and typically has “cloud-like” 
appearance (Fig 12F, inset).  These actin clouds are often positioned at the ends of actin stress 
fibers, suggesting that actin filaments may either radiate from, or terminate in, these structures.  
Shrm4 is also associated with tightly bundled actin filaments that are more reminiscent of stress 
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fibers, although they are not on the surface of the cell contacting the underlying substrate.  Stress 
fibers are composed of a contractile acto-myosin network [154], so IF was used to determine if 
non-muscle myosin II (NMMII) is a component of these Shrm4-actin structures.  Indeed, myosin 
II is a part of the Shrm4-actin based structures (Fig. 12G).  This result is not too surprising, based 
on the ability of Shrm3 to recruit myosin II to the apical surface of MDCK cells in an ASD2 
dependant manner [136].  Since primary mouse cells are often not a homogenous population of 
cells (sometimes comprising dozens of cell types), it was important to find a cell line that 
endogenously expresses Shrm4.  Based on the expression of Shrm4 in the vasculature, various 
endothelial cell lines were examined for Shrm4 expression. 
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         Figure 12: Sub-Cellular Localization of mShrm4 in Primary Mouse Cells 
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Figure 12: Sub-cellular Localization of Shrm4 in Primary Mouse Cells 
Cell derived from e10.5 mouse embryos were stained to detect either Shrm4 alone (A-E),  Shrm4 and 
actin (F, green and red respectively), or Shrm4 and non-muscle myosin II (NMMII) (G, green and red 
respectively).  In primary mouse cells, Shrm4 most often displays a filamentous/vesicular distribution (A-
C), however patterns reminiscent of focal adhesions (D) and membrane localization (E) are also 
observed.  The Shrm4 filaments are coincident with a unique population of F-actin (F, arrow), which are 
sometimes observed as actin “clouds” (F, arrowheads).  The boxed region is shown enlarged in the inset.  
Shrm4 also co-localizes with a population of NMMII that is distinct from the stress fiber population (G, 
arrow).  Scale bar equal to 15 μm (A-D, F, G) or 7.5 μm (E). 
 
 
 
3.3.3 Shrm4 is Endogenously Expressed in Some Endothelial Cell Types 
In the quest to find cell types that endogenously express Shrm4, a number of different 
endothelial cell types were examined based on the observation that Shrm4 is co-expressed in 
cells expressing PECAM.  Embryonic brain endothelial cells (bEND) and yolk sac endothelial 
cells (C166) from mice, rat lung microvessel endothelial cells (RLMVEC), and human umbilical 
vein endothelial cells (HUVEC) were all examined for expression of Shrm4 (Fig. 12).  Shrm4 
expression is detected in the bEND and RLMVEC cells by IF and Western blot (Fig 12A, B, E).  
However, Shrm4 is not detected in the C166 or HUVEC cells (Fig 12C and D).  In bEND and 
RLMVEC cells, Shrm4 localizes into the short dense filaments (Fig 12A and B, arrows) similar 
to those observed in the primary mouse cells (Fig 11F).  In addition, the Shrm4 filaments in the 
bEND and RLMVEC cells contain a unique population of F-actin that is not observed in the 
Shrm4 negative C166 or HUVEC cells.   
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                    Figure 13: mShrm4 is Expressed in Endothelial Cells 
 
Figure 13: Shrm4 Expression in Endothelial Cells. 
Immortalized endothelial cells from mice (bEND and c166), rat (RLMVEC), and human (HUVEC) were 
stained to detect Shrm4 (green) and actin (red).  Shrm4 is detected in bEND and RLMVEC cells by IF (A, 
B) and from cell lysates (E).  No Shrm4 expression is detected in c166 or HUVEC cells (C, D).  The 
bEND and RLMVEC cells express a protein of the predicted molecular size when examined by Western 
blot (E).  Shrm4 negative RAT1 fibroblast cells were transiently transfected with Shrm4 (full-length or 
dPDZ) and used as a positive control.  Equal volumes of the cleared cell lysates were loaded onto the gel 
and resolved by SDS-PAGE.  The N-terminal anti-Shrm4 antibody was used for the WB. Scale bar equal 
to 15 μm. 
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3.4 DISCUSSION 
mShrm4 encodes a 1475 amino acid protein that contains an N-terminal PDZ domain and a C-
terminal ASD2 motif, each of which are about 60% similar to the other Shrm family members 
yet notably lacks the conserved ASD1 motif.  Since it does contain the PDZ and ASD2 elements, 
as well as similarly located EVH and PDZ binding sites, it can be placed in the Shrm family of 
proteins.    The presence of a leucine zipper is curious, since leucine zippers are most commonly 
found in regulators of transcription [155]. However this function has not been identified for any 
Shrm protein.  It is most likely that this domain is facilitating a protein-protein interaction 
through the formation of a coiled-coil interaction [156], or it is a coincidental stretch of leucine 
residues.  The mShrm4 protein is roughly 80% identical to hShrm4, with the PDZ and ASD2 
motifs at 98% and 94% identical, respectively.  As mentioned previously, this domain structure 
is more reminiscent of the invertebrate orthologs [135], indicating a gene duplication event.  
Even though there seems to be no identifiable ‘domain’ in the central region of Shrm4 and no 
homology to any known proteins, there does appear to be a short (~20 amino acids) sequence 
that is conserved.  Short sequences such as these could perhaps reveal a yet unidentified 
functional domain, but more research is necessary to determine if these stretches of sequence 
represent a conserved function or are merely a coincidence.   
The Shrm4 protein is ubiquitously expressed during early embryonic development and 
persists into adulthood.  Much like the other Shrm family members, Shrm4 is expressed in 
tissues that contain highly polarized cell types (such as the lung and kidney) and in fact is co-
incident with the epithelial cell markers ?-catenin, ZO-1, and E-cadherin and the endothelial 
marker PECAM.  Expression of Shrm4 in the vasculature could be the explanation for the 
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observed ubiquitous expression, since all tissues are vascularized.  It will be interesting to 
determine if Shrm4 does play a role in vascular development (discussed in section 6.4). 
The sub-cellular localization of Shrm4 is also quite interesting.  In both the primary 
mouse cells and the endothelial cell lines, Shrm4 is co-incident with a distinct population of 
actin.  This is striking because the ASD1 domain, which is required for targeting Shrm2 and 
Shrm3 to actin, is not present in the Shrm4 protein.  The co-incident localization of Shrm4 with 
NMMII is not too surprising since it is the ASD2 domain that facilitates this interaction for 
Shrm3.  The association of Shrm4 with actin and NMMII will be described in section 4.3, but it 
is important to address the unique actin clouds.  The ‘actin-clouds’ described in the primary 
mouse cells are composed of a dense actin core with filaments of F-actin seeming to radiate out 
of this structure.  These structures are quite reminiscent to those seen in the early assembly of 
filopodia [157] [22].  In these studies, the actin ‘stars’ represent the early formation of filopodial-
like bundles (in the absence of capping protein), and their genesis is dependent on the Arp2/3 
complex, as well as the EVH1 domain protein WASP.  mShrm4 contains an EVH1 binding 
ligand (which have been shown to be critical for actin dynamics [158]) and can bind (and 
bundle) F-actin (Figs 24 and 25) [149].  Based on the sequence elements and the sub-cellular 
localization alone, Shrm4 seems a likely candidate for being a regulator of F-actin dynamics.  It 
is interesting to speculate that Shrm4 may play a pivotal role in directing the architecture of actin 
filaments to facilitate the development and maintenance of the vasculature.   
 
 67 
4.0  SUB-CELLULAR LOCALIZATION AND FUNCTIONAL STUDIES OF 
mSHROOM4  
4.1 INTRODUCTION 
The endogenous distribution of mShrm4 in tissue sections and in cell culture makes it an 
intriguing candidate for regulating the actin cytoskeleton in the vasculature.  The sub-cellular 
localization pattern of mShrm4 does not resemble the sub-cellular localization patterns observed 
for any of the other Shrm proteins [120, 135].  Shrm2 and Shrm3 both localize to the AJC at the 
plasma membrane, where they are coincident with the TJ marker ZO-1 and with the cortical 
population of F-actin [120, 135].  In addition, Shrm2 is associated with a basal population of F-
actin in endothelial cells [135], and Shrm3 can bind to the actin-rich stress fiber network [120].  
It is hypothesized that the sub-cellular localization may be a critical regulatory step that allows 
these proteins to function properly within the cell and effect cell shape [135, 136].  mShrm4 does 
not endogenously localize to the AJC nor does it decorate actin stress fibers.  However, mShrm4 
does co-localize to distinct sites that are composed, in part, by a dense actomyosin network 
[149]. 
In order to better comprehend the sub-cellular localization pattern and function of 
mShrm4, it is first necessary to understand the nature of the observed Shrm4-actin structures.  
The endogenous localization of mShrm4 often appears vesicular or assumes the morphology of 
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elongated or tubular vesicles/organelles [159, 160].  In addition, the co-localization of mShrm4 
with actin is extremely interesting as it does not contain a conserved actin-binding ASD1 
domain, nor does it share similarity to any known actin binding protein.  As mentioned 
previously, actin does play a major role in the endocytic pathway, and the associated vesicles are 
typically linked to a population of actin [161].  The following section will examine the nature 
mShrm4 sub-cellular localization. 
4.2 ECTOPICALLY EXPRESSED mSHRM4 MIMICS THE ENDOGENOUS 
LOCALIZATION 
4.2.1 Ectopic Expression of mShrm4 
When expressed in HEK293 cells, the myc-mShrm4 construct produces a protein product that is 
the correct size (Fig 9A, B) and localizes in a similar sub-cellular pattern as the endogenous 
mShrm4 protein (compare Figs 9C and 12).  Does mShrm4 localize to unique F-actin based 
structures and is this a cell type specific event?  To address this question, the myc-mShrm4 
construct used previously was transfected into a number of cell types, including endothelial and 
fibroblastic cells.  Indeed when mShrm4 is transiently transfected into bEND, C166, HUVEC, 
and RAT1 fibroblasts, the sub-cellular localization of ectopically expressed mShrm4 is 
indistinguishable from that of the endogenous pattern (compare Fig 11F to Fig 14A-D) (NOTE: 
In the bEND cells, the endogenous mShrm4 protein is expressed at significantly lower levels 
compared to the ectopically expressed protein).  Not only does exogenous Shrm4 exhibit the 
correct distribution in these cells, but it can also enhance the formation of the actin-based 
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structures (Fig 14A”-D”, arrows).  This enhancement is most apparent in the C166, HUVEC, 
and RAT1 cell lines, where the untransfected cells do not obviously contain these structures 
(compare the starred cell in Fig 14B” or 14C” to the other cells in those panels).  In fact, greater 
than 80% of the cells expressing ectopic mShrm4 exhibit these actin-based structures (which also 
contain mShrm4), while less than 3% of the untransfected cells display these F-actin structures 
(n = >> 50 transfected or control cells using RAT1 and HUVEC cells in multiple independent 
experiments).  These results indicate that mShrm4 may be inducing cytoskeletal reorganization 
or stabilizing/amplifying a pre-existing structure.  However, since these structures still have the 
appearance of elongated tubules or vesicles, it was next necessary to establish if this observation 
were valid.  
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                                Figure 14:Ectopic Expression of mShrm4 
Figure 14: Ectopic Expression of mShrm4 
Ectopic mShrm4 localizes to actin-rich structures. bEND (A), C166 (B), HUVEC (C), and RAT1 
fibroblast (D) cells were transiently transfected with full-length Shrm4 expression vectors and stained to 
detect both Shrm4 (green) and actin (blue, A and B; red C and D).  Arrows indicate the co-localization of 
Shrm4 with actin.  In C166 and HUVEC cells, these actin-based structures (arrow) are seen in transfected 
cells (star) but not in untransfected cells (see text). Scale bars equals 15 μm. 
 71 
 
4.2.2 mShrm4 is Not Associated with Endosomal Components  
As previously described, the endocytic pathway depends on the actin cytoskeleton and the 
activity of various myosin motors [159].  The short dense actin-rich mShrm4 structures are 
somewhat reminiscent of endocytic vesicles or elongated organelle structures.  Many of the 
components that comprise these vesicles are well documented and serve as excellent markers for 
comparison.  The GTP binding proteins Rab5 and Rab7 are associated with early and late 
endosomes, respectively, and can be used to mark these two parts of the endocytic pathway 
[162].  Ectopically expressed mShrm4 does not co-localize with Rab5 or Rab7 (Fig 15A, B), 
indicating that mShrm4 is not part of the endocytic pathway.  To more fully explore the 
possibility that mShrm4 is associated with vesicles, cells transiently transfected with mShrm4 
were incubated with TRITC-dextran for 24 hours to label all intracellular vesicles.  Dextran is 
internalized by macropinocytosis from the surrounding media and subsequently incorporated and 
recycled through the endocytic pathway.  mShrm4 does not co-localize with any TRITC-dextran 
positive structure (Fig. 15C).  An alternative pathway that cells will often utilize for intracellular 
transport is that of the caveolae-coated vesicles.  mShrm4 does not associate with caveolin 
coated vesicles (Fig. 15D).  These results suggest that mShrm4 is not associated with 
components of the endocytic or caveolin-mediated intracellular transport pathways.  Based on 
the localization pattern of mShrm4 that frequently appears globular or tubular, it still remains 
possible that mShrm4 is associated with membrane-bound organelles, such as the Golgi 
apparatus or the mitochondria.  These organelles often assume a vesicular type of appearance 
themselves, which sometimes makes separating organelle from vesicle an arduous task.  
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To test this possibility, mShrm4 was transiently co-transfected into HEK293 cells with an 
ornithine transcarbamylase (OTC) expression construct that has an N-terminal fusion to green 
fluorescent protein (GFP) (Fig 16A).  OTC is a mitochondrial enzyme involved in the urea cycle, 
and therefore this construct will label the mitochondria.  There is no apparent co-localization 
between the GFP-OTC and mShrm4 (Fig 16A).  Additionally, mShrm4 does not co-localize with 
the Golgi marker, giantin, nor do the structures show any morphological changes when subjected 
to treatment with brefeldin A (a toxin that blocks vesicular transport) (Fig 16B, C)[163, 164].  
These data indicate that mShrm4 is not associated with membranous structures, such as 
intracellular vesicles or organelles, and that the structures with which mShrm4 is associated, are 
more likely ‘mechanical’ in nature.  Since the population of actin that is co-incident with 
mShrm4 is unique, it is necessary to determine if mShrm4 localization depends on an intact 
cytoskeleton. 
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                 Figure 15: mShrm4 is Not Associated with Endocytic Vesicles 
Figure 15: mShrm4 is Not Associated with Endocytic Vesicles 
HEK293 cells were transiently transfected with mShrm4 (green) stained to detect Rab5 (A), Rab7 (B), or 
Caveolin-1 (D) (red).  mShrm4 expressing HEK293 cells were also incubated with TRITC-dextran (red) 
for 24 hours and stained to detect mShrm4 (green) (C).  mShrm4 was detected with the mShrm4 specific 
primary antibody.  Secondary antibodies were either Alexa-488 (green) or Alexa-568 (red) conjugated.  
Scale bars are equal to 15 μm (A-C) or 10 μm (D). 
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                    Figure 16: mShrm4 is Not Associated with Organelles 
 
Figure 16: mShrm4 is Not Associated with Organelles 
 
HEK293 cells were transiently transfected with mShrm4 and GFP-OTC (A) or mShrm4 alone (B, C).  
mShrm4 (red) does not co-localize with mitochondria (green) (A).  mShrm4 (green) is not associated with 
the Golgi (red) (B) nor is its localization effected by treatment with brefeldinA (C).  Scale bars equal 15 
μm. 
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4.3 mSHRM4 LOCALIZATION DEPENDS ON THE ACTIN CYTOSKELETON 
4.3.1 An Intact Actin Cytoskeleton is Necessary for mShrm4 Localization 
The next step in understanding the sub-cellular function of mShrm4 is to determine the 
relationship between F-actin organization and mShrm4 distribution.  CytochalaisinD (CD) is a 
well-known inhibitor of actin polymerization and is commonly used to cause the breakdown of 
F-actin based structures [121].  Treatment of HUVEC cells expressing exogenous mShrm4 with 
2 μM CD completely disrupts the distribution of both mShrm4 and F-actin (Fig 14C versus Fig 
17A).  However, despite the overall lack of cytoskeletal organization following CD treatment, 
Shrm4 remains co-distributed with F-actin.  This observation indicates that the sub-cellular 
distribution of mShrm4 is dependent on an intact actin cytoskeleton and that mShrm4 may be in 
a complex with F-actin.  In contrast, mShrm4 localization is not dependent on microtubules, as 
treatment with nocodozole (33 μM) does not alter its localization (Fig 17B).  Endogenous 
mShrm4 localization is also dependant on an intact cytoskeleton, as treatment of bEND cells 
with 2 μM CD causes mShrm4 to collapse with actin (Fig 17C).  This phenotype is not 
permanent and can be rescued by removing the CD and allowing the cells to recover (Fig 17D).  
Since the mShrm4-actin structures are also co-incident with a population of non-muscle myosin 
II, it is necessary to examine the role of myosin II in the establishment of these structures. 
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     Figure 17: mShrm4 Localization  is Dependant on the Actin Cytoskeleton 
 
Figure 17: mShrm4 Localization is Dependant on the Actin Cytoskeleton 
(A and B) HUVEC cells transiently transfected with Shrm4, were treated with either 2μM cytochalasin D 
(A) or 33 μM nocodozole (B) and stained to detect Shrm4 (A and B, green), actin (A, red), or tubulin (B, 
red).  (C and D) bEND cells were treated with 2μM CD and either stained to detect mShrm4 (green) and 
actin (red) or the CD was removed from the media, the cells allowed to recover for 3 hours, then stained 
as in C. Scale bar equal to 15 μm. 
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4.3.2 The Morphology of mShrm4 Structures Requires Functional NMMII  
It has been shown that Shrm2 and Shrm3 co-distribute with myosin II in non-muscle cells and 
that Shrm3 requires myosin II to cause constriction [135, 136].  Since some F-actin based 
structures (such as stress fibers) are dependent on the activity of myosin II, the localization of 
mShrm4 in vascular endothelial cells was examined following the treatment of cells with 
blebbistatin, an inhibitor of myosin II activity [165].  In both C166 and bEND cells, ectopically 
or endogenously expressed mShrm4 and myosin II co-distribute as is seen in primary fibroblasts 
(Fig. 18A, B versus Fig. 11G).  In fact, mShrm4 appears to recruit myosin II to this locale, as 
very little or no myosin II exhibits this localization in untransfected cells (Fig. 18A, starred vs. 
unstarred cell).  Treatment of bEND and transfected C166 cells with blebbistatin effectively 
eliminates actin stress fibers but does not eliminate the association of Shrm4 with actin or the 
formation of the actin structures to which mShrm4 and myosin II are localized (Fig. 18C and 
18D).  However these structures are less prominent and are typically more globular, particularly 
in cells over expressing Shrm4 (Fig. 18C).  Similarly, when cells are treated with CD and 
blebbistatin simultaneously, followed by removal of CD and recovery in the presence of blebb, 
the characteristic mShrm4 structures do not reform (Fig 19A).  Yet, mShrm4 still associates with 
actin, again in a dense globular type of pattern (19A, arrow).  These data suggest that myosin II 
activity is required for formation, and likely, the maintenance of the Shrm4 -F-actin structures.     
In addition, bEND cells treated with effectors of the myosin II pathway (both positive 
and negative) disrupt the normal localization pattern of mShrm4 without disrupting the 
association with F-actin.  Rho activation of myosin II through ROCK is a well-known pathway 
(described above) [166], and much effort has been put forth to generate specific inhibitors and 
activators to each step.  The ROCK inhibitor, Y-27632, effectively blocks all ROCK-dependant 
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activities [167].  When bEND cells are treated with this compound, the stress-fiber network 
breaks down, but the cortical population of actin remains intact.  However, mShrm4 remains 
associated with the cortical population of F-actin in a globular morphology, similar to the 
blebbistatin treated cells (19B).  Conversely, activation of myosin II with calyculin A, an 
inhibitor of myosin phosphatase [168], seems to stimulate the number and density of the 
mShrm4-actin structures (Fig. 19C).  In addition, the mShrm4 seems to localize specifically to a 
population of F-actin that forms a circle around the center of the cell.  (*These results have not 
been quantified and more repetitions are necessary to validate this hypothesis).  While the Shrm-
4-actin-myosin structures are maintained in the presence of blebbistatin, it is currently unclear if 
myosin II activity is required for the formation of these structures. 
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           Figure 18: Morphology of mShrm4 Structures Depends on NMMII 
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Figure 18: Morphology of mShrm4 Structures Depend on NMMII 
 
C166 (A and C) and bEND (B and D) were used to examine mShrm4 and NMMII interactions.  C166 
cells were transiently transfected and stained to detect mShrm4 (green) and NMMII (red).  bEND cells 
were stained to detect endogenous mShrm4 (green) and NMMII (red).  mShrm4 co-localizes with NMMII 
in dense structures (A and B, arrows) that are also positive for actin (not shown).  In fact, ectopically 
expressed mShrm4 causes the formation of these large NMMII structures when compared to the 
untransfected control (A, starred cell vs. unstarred cell).   Treatment with 200 nM blebbistatin for 90 (C) 
or 180 (D) causes the reduction/loss of stress fibers, but mShrm4 remains associated with NMMII in more 
globular type structures (arrow).  Scale bars equal 15 μm, except in B (5 μm). 
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     Figure 19: mShrm4 Localization and Morphology Depend on Functional NMMII  
 
Figure 19: mShrm4 Localization and Morphology Depend on Functional NMMII 
bEND cells were treated with various chemicals that effect the Rho-ROCK pathway.  Cells were treated 
with CD and recovered in the presence of blebbistatin (CD+blebbistatin, A), the ROCK inhibitor Y-
27632 (B), or the myosin phosphatase inhibitor CalyculinA (C) and stained to detect mShrm4 (green) and 
actin (red in A, C and blue in B).  mShrm4 remains associated with actin after treatment with 
CD+blebbistatin or Y-27632, but assumes a globular morphology (A and B, arrows).  Constitutively 
active myosin II causes the stress fibers to contract and shorten, however the mShrm4-actin structures 
seem more prominent and perhaps elongated (C).  Scale bars equal 15 μm.  
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4.4 DISCUSSION 
The ability of the Shrm family of proteins to reorganize the actin cytoskeleton has been well 
documented and the mechanism of function is slowly being elucidated [135, 136].  Shrm3 binds 
to a population of F-actin at the apical surface of cells, recruits myosin II, and facilitates the 
constriction of the apical actin belt.  This process has been shown to be dependent on ROCK 
activity, but not its activator RhoA.  While the localization pattern of mShrm4 is unlike any of 
the other Shrm proteins, the resultant structures share the components that are key to Shrm 
function, actin and myosin II.  
mShrm4 can induce the formation of short, dense actomyosin structures (which also 
contain mShrm4).  Exogenous expression of mShrm4 in cells that do not normally express 
Shrm4, causes a robust increase of these actin structures (Fig 14C, D) and endogenous mShrm4 
is almost always associated with unique actin rich structures.  In fact, mShrm4 is not just 
associated with actin, but it is dependent on an intact actin cytoskeleton for proper localization.  
Since myosin II is present in these structures, a similar question can be asked about myosin II’s 
role in the mShrm4 structure.  Indeed, mShrm4 requires the activity of myosin II to maintain the 
normal morphology of the structures.  Treatment of cells with inhibitors to the myosin II 
pathway leads to the formation (or the “un-formation”) of small, globular structures that remain 
rich in actin, myosin II, and mShrm4.  These data indicate that mShrm4 probably facilitates the 
formation and/or maintenance of the actin-rich structures through the activity of myosin II, not 
unlike the mechanism observed for Shrm3 [136].  The mShrm4-actin structures do not appear to 
play a role in vesicular transport, so they are perhaps playing a role in the global 
cytoarchitecture.  The rigid association of mShrm4 with actin is quite curious, since it lacks the 
ASD1 actin-binding domain and it has no homology to any other known actin-binding protein.  
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The collapse of a protein with actin in response to CD treatment is a hallmark phenotype of an 
actin-binding protein.  This observation begs the question: Does mShrm4 bind directly to actin? 
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5.0  mSHRM4 BINDS ACTIN WITH A NOVEL ACTIN BINDING DOMAIN 
5.1 INTRODUCTION 
Actin regulation is best accomplished by proteins that can bind directly to G-actin or to F-actin.  
These proteins (discussed in more detail in section 1.0) not only regulate the kinetics of actin 
assembly [169] but also facilitate the ‘downstream’ function of actin filaments, such as muscle 
contraction or cytokinesis.  Both Shrm2 and Shrm3 are actin-binding proteins that affect cell 
shape change through an actomyosin-based mechanism [136].  The Shrm proteins bind actin via 
their ASD1 motifs; and the ability to bind to actin is critical for Shrm function [120, 135].  It has 
been shown that Shrm3 binds actin in an ASD1-dependent event and recruits myosin II to the 
Shrm3-actin complex.  In this complex, myosin II is activated by way of ROCK and causes 
constriction of the actin filaments [136].  In addition to binding directly to actin, Shrm3 (but not 
Shrm2) is able to induce actin bundles, a function also mediated by the ASD1 motif [135].  The 
conserved ability of the Shrm family to bind to actin via the ASD1 motif posits an interesting 
scenario. 
Shrm4 has many of the conserved features of the Shrm family, including the PDZ domain 
and the ASD2 motif, but lacks the actin-binding region of ASD1.  Surprisingly, mShrm4 remains 
closely associated with regions of dense actin structures in cell culture and remains associated 
even when the cells are treated with chemicals that disrupt the normal organization of F-actin. 
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mShrm4 has a unique sub-cellular distribution compared to that of Shrm3 and of Shrm2, and it is 
most likely that this distribution provides the differential function of the proteins.  Since mShrm4 
belongs to a family of actin-binding proteins and displays an actin dependent sub-cellular 
localization, the question still remains as to whether or not mShrm4 can directly bind to actin, 
despite lacking the ASD1 motif.  The following section will investigate the actin binding ability 
of mShrm4. 
         
5.2 mSHRM4 HAS AN ACTIN LOCALIZATION MOTIF 
To define the localization motif, a series of vectors were generated that express different regions 
of mShrm4 protein, each containing an N-terminal myc-tag (Fig 20A).  Transient transfection of 
these plasmids into cells results in the expression of proteins of the expected molecular mass (Fig 
20B).  To test for sub-cellular localization, C166 cells were transiently transfected with each of 
these vectors and stained to detect the ectopically expressed protein.  The C166 cells were used 
because they are a relevant cell type; they are readily transfected; mShrm4 exhibits the correct 
localization in these cells; and mShrm4 expression induces the robust formation of the actin-
based structures observed in primary cells.  In C166 cells, both full-length Shrm4 (Fig 13B) and 
Shrm4-?PDZ (?PDZ, Fig 20C) exhibit the normal filamentous staining pattern observed for 
endogenous Shrm4.  Deletion of the C-terminal ASD2 motif (?ASD2, Fig 20D) does not 
eliminate localization but results in a much more diffuse distribution relative to that of either 
full-length Shrm4 or Shrm4-?PDZ.  Proteins consisting of amino acids 1-522 (containing the 
PDZ domain) and 1180-1475 (ASD2) are completely cytoplasmic, indicating that neither of 
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these regions is sufficient for determining proper localization (Fig 20E and 20H, respectively).  
These results suggested that the central portion of Shrm4 targets the protein to actin-based 
structures.  To test this, the central region of Shrm4 (amino acids 436-1180 or 436-966) was 
expressed and assayed for sub-cellular localization.  These two Shrm4 proteins exhibit a 
localization pattern that is different from that of full-length Shrm4 in that they target to the cell 
periphery (Fig. 20F and 20G).  Co-staining to detect 435-1180 or 436-966 and F-actin indicates 
that these proteins are localized primarily to the cortical actin cytoskeleton (Fig. 21A and 21B).  
These data suggest that the central region of Shrm4 regulates its localization to the cytoskeleton, 
but additional sequence motifs may function to define the specificity of this localization.   
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                  Figure 20: Mapping of the mShrm4 Targeting Sequence 
 
Figure 20:  Mapping of the Shrm4 Targeting Sequence. 
 
(A)  Schematic of the various proteins used to map the sequences required for proper localization of 
Shrm4.  All constructs have an N-terminal myc tag. 
(B)  Western blot of lysates from MDCK cells expressing the constructs depicted in (A).  Lysates were 
probed with the 9E10 anti-myc antibody. 
(C-H)  C166 cells were transiently transfected with expression vectors for the indicated Shrm4 variant 
and stained to detect Shrm4. Scale base equals 15 μm. 
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5.3 mSHRM4 IS AN ACTIN BINDING PROTEIN WITH BUNDLING 
CAPABILITIES 
To determine if the localization of mShrm4 to the cytoskeleton is mediated by direct binding to 
F-actin, purified GST-mShrm4 fusion proteins consisting of amino acids 436-966 (arrowhead) or 
436-1180 (arrow) were tested for the ability to co-sediment with purified F-actin (Fig 21C).  In 
this experiment, increasing amounts of the purified GST-mShrm4 proteins were incubated with a 
fixed amount of F-actin (Fig 21C lanes 6-14, asterisk).  GST-mShrm4 will not pellet 
independently at  100,000 x g (Fig 21C lanes 1,2), however F-actin will pellet at this speed (Fig 
21C, lanes 4,5).  As increasing amounts of GST-mShrm4 are added to the F-actin, increasing 
amounts of GST-mShrm4 are found in the pellet fraction after the centrifugation (Fig 21C, lanes 
6-14, arrowhead and arrow).  Since F-actin is the only species capable of pelleting in this 
reaction, GST-mShrm4 must be bound to the actin filaments in order to pellet at these speeds.   
Interestingly, there is a common degradation product found in the GST-mShrm4 protein sample 
(Fig 21C, oval) that does not retain the ability to bind to actin.  Examination of this product could 
provide insight into the sequence requirements for actin binding.  
Since the Shrm family displays a differential ability to bundle actin (Shrm3 can bundle F-
actin whereas Shrm2 can not), mShrm4 was tested for the ability to induce higher-order actin 
structures.  In these experiments, the actin-binding region of mShrm4 (amino acids 436-966 and 
436-1180) was purified as N-terminal GST-fusion proteins (as described above) and used to test 
examine their ability to cross-link actin filaments.  The actin bundling ability was observed via 
two methods.  After the mShrm4 protein was incubated with F-actin, the sample was either 
labeled directly with TRITC-phalloidin (to label the actin fluorescently) or subjected to a low 
speed centrifugation to pellet the F-actin bundles.  Indeed when mShrm4 is added to F-actin, 
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higher-order actin structures are observed when compared to the controls (Fig 22 D, E compared 
to 22 A-C).  Similarly, mShrm4 and F-actin both pellet after low-speed centrifugation indicating 
that F-actin is assembling into some type of mShrm4 induced higher-order structure (Fig 22 F, 
lanes 6-13).  For comparison, the F-actin without mShrm4 remains in the supernatant under low-
speed conditions (Fig 22F, compare lanes 4 and 5 in the supernatant fraction to the pellet 
fraction).   
These data indicate that mShrm4 binds directly to actin and can, in fact, induce the 
formation of higher-order actin structures.  These properties of mShrm4 are surprising in light of 
the fact that mShrm4 does not have the conserved ASD1 motif. assumed to be required for  actin 
association. 
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                                Figure 21: mShrm4 is an Actin Binding Protein 
 
Figure 21: mShrm4 is an Actin Binding Protein 
(A and B)  C166 cells transiently transfected to express amino acids 436-966 (A) or 436-1180 (B) of 
mShrm4 were stained to detect mShrm4 and actin (green and red, respectively).  Scale bar equal to 15 
μm.  (C) Amino acids 436-966 and 436-1180 of mShrm4 co-sediment with F-actin.  Increasing amounts 
of purified GST-mShrm4 436-966 (arrowhead, lanes 1, 6-9) or 436-1180 (arrow, lanes 2, 10-14) were 
added to a fixed amount of F-actin (asterisk) and centrifuged at 100,000 x g.  GST-mShrm4 fusion 
proteins do not pellet in the absence of F-actin (lanes 1 and 2).  GST alone does not pellet in the absence 
or presence of F-actin (lanes 3 and 5 respectively).  Contaminating breakdown products remain in the 
supernatant fraction (dot, lanes 6-14, supernatant fraction). 
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                Figure 22: mShrm4 can Induce Higher Order F-actin Structures 
Figure 22: mShrm4 can Induce Higher Order F-actin Structures 
A-E.  F-actin was polymerized and incubated with GST alone (C) or GST-mShrm4 fusion proteins of 
amino acids 436-966 (D) or 436-1180 (E) and placed on a coverslip for visualization.  The GST only (A) 
and the actin only (B) controls show no F-actin structures.  All samples were incubated with TRITC-
phalloidin to fluorescently label the actin structures.  F.  Amino acids 436-966 and 436-1180 of mShrm4 
induce higher-order actin structures.  Increasing amounts of purified GST-mShrm4 436-966 (arrowhead, 
lanes 1, 6-9) or 436-1180 (arrow, lanes 2, 10-13) were added to a fixed amount of F-actin (asterisk) and 
centrifuged at 10,000 x g.  GST-mShrm4 does not pellet in the absence of actin (lanes 1 and 2) and 
similarly actin does not pellet in the absence of GST-mShrm4 (lanes 4 and 5).  GST alone does not pellet 
in the absence or presence of F-actin (lanes 3 and 5 respectively).  Contaminating breakdown products 
remain in the supernatant fraction (dot, lanes 6-14, supernatant fraction). 
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5.4 DISCUSSION 
The Shrm family of proteins is a well-known family of actin-binding proteins that facilitate 
various aspects of cytoskeletal organization.  The ability to bind to actin resides in the ASD1 
motif present in Shrm1, Shrm2, and Shrm3, but not in mShrm4.  Actin-binding properties have 
been demonstrated for Shrm2 and Shrm3 [120, 135, 136], but until recently have not been 
observed for mShrm4 [149].  The data here show that mShrm4 can bind directly to actin and 
induce the formation of higher order structures.  These properties are facilitated by a sequence 
that is not conserved among the Shrm family of proteins and in fact has not yet been described 
for any known protein.   
The Shrm family of proteins provides an interesting case for studying actin-binding 
proteins.  Shrm2, Shrm3, and Shrm4 all bind to actin, yet they all bind to different populations of 
actin.  Shrm2 and Shrm3 use the same conserved actin-binding element to bind to these different 
populations, whereas mShrm4 uses a completely novel motif.  These differences indicate that 
there is a series of regulatory elements inherent in the sequences surrounding the actin-binding 
motifs that regulate the actin-binding properties.  In support of this hypothesis, amino acids 436-
966 of mShrm4 are capable of binding actin, yet when expressed in cells and examined by IF, 
this construct targets to a different population of actin than the wild-type protein.  Similarly, the 
ASD1 motif of Shrm3 can bind and bundle actin, whereas the ASD1 motif of Shrm2 can only 
bind (and not bundle) actin.  In addition to regulatory elements inherent in the surrounding 
sequence, the populations of actin could be different in these locations.  Perhaps the differential 
bundling abilities are a result of the conformation of the actin and not a function of the Shrm 
proteins having regulating sequences.  These are interesting questions, whose answers will 
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certainly provide a better understanding of how the dozens of known actin-binding proteins 
decide which population of actin to bind. 
The actin-binding ability of mShrm4 is quite clear, and the actin-binding motif is 
contained within amino acids 436-966.  This motif also retains the ability to induce actin into 
higher-order structures.  One caveat of these experiments is that GST has been shown to 
dimerize, so it is possible that the GST-fusion proteins in these experiments are forming artificial 
dimers.  Based on scenario 2 in Fig 1B, this could falsely cause actin to cross-link due to 
mShrm4’s ability to bind to actin.  Experiments are being performed to address this issue. 
Nonetheless, the data regarding the distribution of myosin II following mShrm4 
expression and previous work showing that the ASD2 motif regulates the distribution of active 
myosin provide an interesting framework with which to speculate about mShrm4 function.   
Since mShrm4 can bind directly to actin, it is hypothesized that mShrm4 and myosin II work 
together to regulate the formation of the observed actin-based structures.   
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6.0  CONCLUSIONS AND FUTURE PROSPECTUS 
6.1 mSHRM4 IS AN ACTIN-BINDING MEMBER OF THE SHRM FAMILY OF 
PROTEINS 
This dissertation describes the cloning and characterization of mShroom4, a member of the 
Shroom family of genes and the mouse ortholog of the SHRM4 gene in humans.  The mShrm4 
protein product is 1475 amino acids in length and is 80% identical to the human protein (>90% 
to the PDZ and ASD2 domains) and shares two of the three conserved sequence elements that 
define the Shrm family: an N-terminal PDZ domain and a C-terminal ASD2 motif.  However, 
mShrm4 lacks the ASD1 motif.  The ASD2 domain is conserved in all known Shrm family 
members, while the PDZ and ASD1 elements are conserved in many, but not all, of the Shrm 
proteins.  Functionally, the PDZ domain does not seem to be required for Shrm3 or Shrm4, as 
deletions of this domain do not affect the localization or the overall function of the proteins 
([120] and this work).  The PDZ domain does seem to enhance Shrm2 localization [135], 
indicating a potential regulatory mechanism for Shrm2 function.  The ASD1 element is present 
in all vertebrate Shrm proteins, except for Shrm4, where it is required for targeting Shrm2 and 
Shrm3 to actin.  The ASD2 element is required in Shrm3 to elicit apical constrictions in 
epithelial cells [136].  The ability to cause apical constrictions is a conserved function of ASD2, 
as the ASD2 motif from any one of the Shrm proteins can functionally replace the Shrm3 ASD2 
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motif in chimeric analysis [135].  Shrm4 possesses the conserved PDZ and ASD2 elements, but 
lacks an actin-binding ASD1 motif.  However, mShrm4 does retain the conserved ability to bind 
directly to actin. 
The differential actin-binding properties of the Shrm family are quite distinct.  Shrm3 
binds to actin stress fibers and bundles them, while Shrm2 is targeted to cortical actin [120, 135].  
Based on these differences, it appears that the activities of the ASD1 motifs from Shrm2 and 
Shrm3 have diverged or are modified by surrounding sequences.  Alternatively, mShrm4 binds 
and bundles F-actin with a completely different sequence.  In fact, the amino acids 436-966 of 
mShrm4 represent, in part, a sequence that defines a novel actin-binding domain.  While this 
domain cannot fully direct the localization of mShrm4, as it localizes to the cortical actin 
population, it can bind and cross-link actin filaments.  Within the actin-binding motif lies a 
sequence element of 25 amino acids that is conserved among the Shrm4 orthologs (Fig 6A) 
across multiple species, with even greater identity between mShrm4 and xShrm4.  It is 
interesting to speculate that this highly conserved sequence represents, at least in part, the novel 
actin-binding motif in Shrm4.  However, since mShrm4 has been shown to facilitate the 
formation of higher-order actin structures, it is possible that another novel actin-binding motif 
exists in this region.  The nature of the cross-linking ability has not been investigated in full, 
therefore it is not possible to determine if mShrm4 contains two actin-binding motifs or if it 
forms homomultimeric mShrm4 complexes that induce the structures.  It is hypothesized that 
Shrm4 represents the most ancestral of the Shrm proteins, because the invertebrate Shrm 
homologs also lack the ASD1 motif and therefore most closely resemble the domain structure of 
Shrm4 [135].  While this could quite possibly be the case, the conserved Shrm4 sequence 
element has not been identified in the invertebrate Shrm proteins.  It will be interesting to 
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investigate the nature of the actin-binding sequence motif and to potentially discover more 
proteins that utilize this element. 
6.2 mSHRM4 REGULATES CYTOSKELETAL ARCHITECTURE 
The sub-cellular localization of mShrm4 represents a unique distribution among known actin-
binding proteins, as this restricted distribution has not been previously described.  The short, 
dense filamentous structures are rich with a unique population of F-actin and NMMII, the two 
main components of a contractile actin network.  In fact, the normal function of NMMII is 
required for maintaining the morphology of the filaments.  These short, dense actin-based 
structures are not observed in cells, which do not express mShrm4.  However, exogenous 
expression of mShrm4 in cells is enough to drive the formation of these structures.  Additionally, 
endothelial cells that endogenously express Shrm4 have a large number of the actin-myosin rich 
structures.   These structures seem to most closely resemble areas of rapid actin assembly or 
nucleation, like the ‘cloud’ structures observed in the formation of filopodia-like structures [21, 
22].  These early filopodial clouds are induced by manipulating the system and using purified 
proteins, but nonetheless provide some insight into how actin-regulatory proteins can induce 
unique F-actin based structures.  The mShrm4-based structures could provide an excellent 
system to better understand the assembly of actomyosin-based complexes in general.  Thus far, 
the physiological purpose of the mShrm4-induced filaments has been elusive.  Most cell types do 
not need Shrm4 for their normal function and, in fact, only a few cell types endogenously 
express mShrm4.  To date, endothelial cells are the only cell types that have been identified as 
Shrm4 expressing cells.  In support of this observation, the vasculature of developing mouse 
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embryos and some adult tissues (Fig 9 and 10) are greatly enriched for mShrm4 expression.  
These two observations, in addition to mShrm4’s actin-binding ability, provide the basis for the 
hypothesis that Shrm4 functions to regulate the actin cyto-architecture in endothelial cells.   
To date, research on mShrm4 has been focused on its sub-cellular mechanism of 
function.  A model of mShrm4 function can be proposed which incorporates the current data into 
a number of predictive steps.  Figure 23 represents the most plausible mechanism of action, 
which can be separated into two major hypotheses.  Steps 1-3 address the modular actin-binding 
ability of mShrm4, while steps 4 and 5 focus on the assembly and organization of the mShrm4-
actin based structures.   
The first testable hypothesis addressed by the model is that mShrm4 binds to a specific 
population of actin through intrinsic regulatory motifs (Fig. 23, steps 1 and 2).  This hypothesis 
stems from the observation that mShrm4 is only bound to a small population of actin in the cell 
while the actin-binding motif (amino acids 436-966) is directed to a cortical population of actin, 
but can still bind directly to F-actin in vitro.  The in vitro experiments utilize only purified 
components (mShrm4 and F-actin), so it is possible that some accessory protein(s) bound either 
to F-actin or to mShrm4, could direct the in vivo specificity of mShrm4 binding to actin.  In 
order to address the possibility of mShrm4 having intrinsic regulatory motifs, a number of 
experiments can be performed.  These are discussed in section 6.4.  Briefly, the minimal region 
of mShrm4 that localizes similar to wild type will be identified.  Once defined, this ‘regulatory’ 
region will be tested for its ability to bind F-actin through co-sedimentation assays.  Ideally, this 
region of mShrm4 will not promiscuously bind F-actin in vitro (no sedimentation), indicating 
that an external factor is necessary to specifically direct mShrm4 to actin or to perhaps modify a 
specific population of actin for mShrm4 to bind.   If the specificity is regulated by external 
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factors, a couple of approaches can be employed that identify a potential interaction.  Two-
hybrid experiments or co-immunoprecipitation and mass spectrometry can be used to identify 
proteins that interact with mShrm4.  However, these experiments do not address the possibility 
that the actin itself may be modified.  Assays will need to be developed that would allow the 
specific isolation of the mShrm4-actin complex, so the actin can be more closely examined.   
 The second hypothesis that the model can address is that mShrm4 directs the de 
novo formation of actomyosin-based structures (Fig. 23, steps 3-5).  This hypothesis is based on 
the observation that ectopic expression of mShrm4 in cells correlates with the appearance of the 
actin-based structures.  Given that mShrm4 binds to a specific population of actin, how does this 
interaction facilitate the assembly of the short, dense actomyosin-rich structures?  In order to 
address this question and test the hypothesis, an assay would need to be designed to enable the 
formation and assembly of the structures to be observed from start to finish.  A few potential 
experiments to address this hypothesis are also described in section 6.4.  Live video microscopy 
would need to be used with cells that express fluorescently labeled mShrm4, actin, and/or 
myosin II.  Since one question addresses the hierarchy of assembly, the observations would 
ideally begin with all three proteins unbound to each other.  This type of regulation could be 
attained if mShrm4 were under the control of an inducible promoter.  Once induced, mShrm4 
would conceivably bind to actin (steps 1 and 2), recruit myosin II (step 4), which in turn would 
help to cross-link the actin filaments and provide a mechanical force to create the dense structure 
(step 5).  The key to this assay is to establish a cell line that expresses fluorescently labeled actin 
and myosin, which will likely lead to very high background since these are both abundant 
proteins.  Once this cell line is established, effectors of actin dynamics and myosin II function 
could be used to help identify how the structures are formed and the role that myosin II plays in 
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their formation (also discussed in section 6.4).  Since a function for the mShrm4-actin structures 
has been elusive thus far, the model is based on formation rather than function.  Experiments 
designed to address function, such as creating Shrm4 knockout mice, are described in section 
6.4.  However, in order to determine how the mShrm4-actin structure is related to the overall 
actin cytoskeleton, high-resolution electron microscopy may be used to reveal this relationship.  
Similar to the work of Svitkina and Borisy in identifying filopodial precursors [21] [170], high 
resolution of the mShrm4-actin-based structure may provide insight into how it is linked to the 
cell or how it serves as a reservoir or an anchor for F-actin.   
 The proposed model in Figure 23 suggests a potential mechanism for how the 
mShrm4-actin rich structures form de novo.  Based on the data, a few hypotheses can be 
proposed and tested based on the predictions of the model.  The experiments described above 
and in section 6.4 are aimed at addressing these hypotheses and ultimately uncovering the 
function of mShrm4.  By identifying how mShrm4 is directed to a specific population of actin, a 
greater understanding of how actin-binding proteins in general are specifically targeted to some 
populations of actin but not others. 
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                                   Figure 23: Model of mShrm4 Function 
 
Figure 23: Model of mShrm4 Function 
This model is based on the data for mShrm4 and for the established function of the ASD2 domain.  The 
initial assumption is that mShrm4 and F-actin co-exist in the cell (1), where mShrm4 binds to a specific 
population of F-actin with the novel actin-binding motif (orange) (2).  The mShrm4-F-actin complex is 
then targeted to a specific location within the cell (3), potentially with the assistance of a yet unidentified 
protein.  Myosin II is then recruited to the mShrm4-actin structure and arranged within the actin complex 
under the direction of mShrm4 (via the ASD2 domain, gray) (4).  Once all of the components are in place, 
mShrm4 facilitates a myosin-based constriction of the actin, thereby forming the dense mShrm4-actin 
structures (5). 
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6.3 mSHRM4 AND X-LINKED MENTAL RETARDATION 
Mutations in various regions of hSHRM4 have been associated with cases of XLMR [133].  
Among the cases of SHRM4 induced XLMR, only one has been identified as a missense 
mutation.  This mutation is a serine (S) to leucine (L) exchange at a site that is not conserved 
between humans and mice (in mice the equivalent position is occupied by a proline (P) residue).  
This residue does not fall into any of the conserved regions, although it is located 10 amino acids 
N-terminal to the putative EHV1 binding site.  The causal effects of the lesions in SHRM4 in 
XLMR have not yet been elucidated and until the sub-cellular function of Shrm4 is better 
understood, this relationship will remain a mystery. 
The tissue localization and sub-cellular distribution of mShrm4 place it in an interesting 
location for a role in XLMR.  All developing tissues depend on the vasculature to provide 
nutrients and oxygen to enable normal growth and development.  Perturbations in blood flow can 
have grave effects on developing tissues, especially the on the highly sensitive cells of the 
nervous system.  As an example, mutations in the gene associated with Norrie disease, NDP, 
(Norrie Disease, pseudoglioma) perturb the normal development of the retinal and cochlear 
vasculature [171, 172].  mShrm4 is highly expressed in endothelial cells of the vasculature in 
both embryonic and adult tissues.  Because mShrm4 represents a novel actin-binding protein that 
is able to direct the organization of contractile actomyosin structures by recruiting actin and 
NMMII, it is plausible that Shrm4 is necessary for proper vascular development.  Shrm4 is also 
expressed in many adult tissues, indicating a continued function in adulthood.  The adult 
vasculature also depends on the de novo formation of new vessels, so it is quite probable that 
Shrm4 functions to direct the development and maintenance of adult vasculature, also in an actin 
dependent manner.  Both vasculogenesis and angiogenesis are processes that, much like the other 
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morphogenetic movements described in this dissertation, depend on the actomyosin network to 
facilitate cell shape changes.  The endothelial cells in these systems require the coordinated 
functions of the downstream effectors of VEGFR-2 (vascular endothelial growth factor receptor) 
and of integrin signaling.  Both of these pathways depend on the function of the RhoA-ROCK 
pathway [173].  Signaling through receptor tyrosine kinases, specifically VEGFR-2 (vascular 
endothelial growth factor receptor 2), can promote the activation of RhoA, which induces ROCK 
and promotes assembly and disassembly of stress fibers [174].  Additionally, the activated 
RhoA-ROCK complex is able to phosphorylate FAK, which then is able to promote focal 
adhesion turnover [175]. 
Alternatively, mShrm4 could be expressed in a population of neuronal cells at a critical 
stage of development.  As described previously, the migration of neurons and the trafficking of 
synaptic vesicles are two processes that are fully dependent on a functional actin cytoskeleton 
(also regulated by the Rho-ROCK pathway).  mShrm4 is observed at the apical and lateral 
portions of  the neural epithelia and is also found in a punctate pattern throughout the neural tube 
(Fig 10).  mShrm4 is certainly in the right place at the right time to affect neural development.  
Perhaps the localization of mShrm4 in specific neural cells is highly stage specific and those 
populations of mShrm4 expressing cells have not yet been observed. 
In order to better test this hypothesis, it will be critical to establish an animal model to 
better understand the role of mShrm4 during early development. 
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6.4 FUTURE PROSPECTUS 
The studies on mShrm4 described here provide a solid foundation to elucidate the function of 
Shrm4.  The ability of mShrm4 to bind to actin coupled with its sub-cellular distribution provide 
an interesting source of speculation for how mShrm4 functions.  In order to better understand 
mShrm4, a number of experiments are necessary, a few of which have already been undertaken 
and other that are in the planning stages.   
Since SHRM4 is implicated in XLMR, it is imperative to determine the developmental 
role of mShrm4.  Two independent experiments are aimed at elucidating this function for Shrm4.  
The first is to create a mSHRM4 null mouse using the genomic clone described in Fig 8.  Regions 
of homology have been identified both 5’ and 3’ of exon 4 of mShrm4 and are currently being 
used to design a targeting vector.  The cloning of this region has thus far proven quite difficult, 
but the construction of this plasmid, and ultimately the Shrm4 knockout mouse, is eminent.  The 
fact that mShrm4 is located on the X-chromosome, the generation of the knockout mice might 
prove to be a daunting experiment.  Additionally, zebrafish can be used as an excellent model to 
examine the developmental role of Shrm4.  In fact, other X-linked mammalian genes implicated 
in XLMR have been studied in zebrafish [176].  Since there is a Shrm4 ortholog in zebrafish, 
morpholino technology can be used to knockdown the endogenous protein and the ensuing 
defects can be visualized.  The first step in this experiment is to determine the localization 
pattern for zShrm4.  Using a riboprobe specific to zShrm4, whole mount in situ hybridizations 
were performed on various staged zebrafish embryos (Fig 24).  At the 18-somite stage, zShrm4 is 
localized to structures that resemble rhombomeres in the developing hindbrain (Fig 24A, arrow) 
[177].  In addition, zShrm4 shows high expression in the tailbud (Fig 24A, arrowhead).  At 44 
hours past fertilization (hpf), the zShrm4 staining is diffuse, yet specifically localized to the 
 104 
anterior region (Fig 24B).  Interestingly, at 72 hpf zShrm4 becomes specifically localized to 
structures that resemble the developing vascular endothelium of the aortic arches (Fig 24C, box) 
[178].  More research is necessary to determine the identity of these structures and more 
importantly to determine the role of zShrm4.  The next step will be to over-express mShrm4 to 
determine if there is an over-expression phenotype.  Conversely, a construct consisting of the 
actin-binding motif (amino acids 436-966) will be expressed to examine the potential dominant-
negative effects on zebrafish development.  If the 436-966 construct does indeed represent a 
dominant negative, it is expected that the phenotype would be similar to a zShrm4 knockdown.  
The knockdown experiment will be conducted using morpholino probes designed from the 
known zShrm4 sequence.  Finally, mShrm4 will be over-expressed to test its ability to rescue a 
zShrm4 knockdown.  In all, the mouse and zebrafish experiments described above should 
provide crucial insights into Shrm4 function and how it could play a role in XLMR and in 
vascular development in general. 
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           Figure 24: zShrm4 Expression in a Developing Zebrafish Embryo 
 
Figure 24: zShrm4 Expression in a Developing Zebrafish Embryo 
Zebrafish embryos were incubated with a digoxygenin-labeled riboprobe specific for zShrm4 at the 18-
somite stage (A), 44 hpf (B), and 72 hpf (C).  At the 18-somite stage, zShrm4 mRNA is localized to 
specific regions in the hindbrain (A, arrow) and in the tailbud (A, arrowhead).  At 44 hpf, zShrm4 is 
specifically localized in the head region but in a diffuse pattern (B).  zShrm4 is expressed in the aortic 
arches at 72 hp (C boxed region).  Inset is a high magnification of the boxed region in C. 
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In order to better understand the sub-cellular function of Shrm4, a number of cytological 
tools can be employed.  Perhaps the most interesting aspect to next examine for mShrm4, would 
be the assembly mechanism of the mShrm4-actin structures.  In order to best understand this 
process, live-image microscopy can be used to observe the initial association of mShrm4 with 
actin and then their assembly into the structures previously observed only by IF on fixed 
samples.  GFP-mShrm4 constructs have been created and transfected into C166 endothelial and 
RAT1 fibroblastic cells in order to generate cell lines that stably express GFP-mShrm4.  These 
cells can be used to observe the formation of GFP-mShrm4 structures de novo.  Additionally, 
these cells could be transfected with alternately labeled actin constructs (such as YFP- or RFP-
actin), so the mShrm4-actin complex can be visualized.  This system will also provide the means 
necessary to utilize the many inhibitors of actin and NMMII dynamics available to test the 
various steps of mShrm4-actin assembly.  These data will provide valuable insight as to how 
mShrm4 is regulated in vivo and will determine if the Shrm family of proteins utilize the 
conserved mechanism for function. 
Finally, the ability of mShrm4 to bind F-actin and induce higher-order F-actin structures 
is very intriguing.  The novel actin-binding motif is poorly characterized and not understood.  
Experiments aimed at further refining the actin-binding motif of mShrm4 are of utmost 
importance in order to fully define this domain.  Biochemistry will be used to empirically 
determine the minimal sequence necessary to bind to actin.  Similarly, the sequence(s) necessary 
to bundle or cross-link F-actin can be determined in this fashion.  The localization motif of 
mShrm4 extends beyond the actin-binding element, therefore these regulatory sequences should 
also be identified.  A series of mShrm4 truncation or deletion constructs will be transfected into 
C166 cells to identify the minimal region of mShrm4 that still localizes to the actin-based 
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structures.  In understanding the mechanism governing mShrm4 localization, a greater 
appreciation for the Shrm family in general can be gained. 
6.5 SUMMARY 
Shrm4 is an unusual member of the Shrm family of proteins.  Unlike the other Shrm proteins, 
Shrm4 utilizes a novel sequence to bind to actin to facilitate the formation of unique F-actin 
based structures.  The function of these structures has yet to be identified, but they clearly play a 
yet uncharacterized role in endothelial cell function.  It will be interesting to discover this role, as 
data from zebrafish and mouse models will surely uncover.  Even more importantly, the 
discovery of Shrm4 function will likely provide a better understanding of neural development in 
general with possible implications to human disease.  
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APPENDIX A 
A.1 PROTEIN SEQUENCE OF DANIO RERIO SHROOM4 
METVEQLVSFQHIHVQLNGGAPWGFTLKGGLEHGEPLIITKGTRPHQTLRQKLVCQPCIQ
HLGSTSRQNHSKVLFALREVPLEKVELLLKNDGVQTYIVGLVKNVMTSSLINEFIQRPNP
PRLVSVNVKYLIHLYGMQHCKIRLGSPFFTAAEAHAPYRLTGESFHAHTLNNMMDTRT
KLIPDALTQGVAEGLSALAASKIEEGGKAAQCKKLRVGDELVNINGSALYGSRQEALILI
KGSYRVLKIIVRRRSVPVIRPHSWHLAKLTEAPCTTGTGDPSDGPPAMQLHFTPLNVPW
HSGGDNSELSMQWGHISRHYSTDRSSSIGSMESLENPPNQGYYDSQLSPIDPVIFNNKRD
SAYSSFSASSNTSDYTVPVKPEETNSMDSLLQGLGSSCRYPDRGQHSAPTGHGNQLEEQ
EHSKVLSGRSEPKVRPSSYSCEEENCAPPQPPMRKESFRATRGQATDKRCVSAPVGIPNV
SSCTDEDQSQIQDVLTGRVYLNGIQDSEPERKGCSIQPYYTLNSDSGGDGKATDHEKEH
LEDYSKSVAAASSPPSQRNRDENFDTKLRPEHDLQSAMNRHSAPEKLLAAQLCMMDVS
ADKSDHSASPTCQWSQSPLYLSDSSQNTEQGKWGTSRCSTPGSVATSEVEDPRLEEESID
GQNPWGHPISLSGSPIGNGFSQNSENNGGEVMLDDGLGPKQPQKRQFRCSKSRRRSERF
ATNLRNEIQRKKAQLQKSRNPCGEETVEEEVGDFNTEVVAPPEYRQHKPQILPKPATNT
VPIQISKPATQKVFDATQTEEYSSARVVCFQTSQTQTQVPQHVRQVCVHVVEEVAPAGK
PRRWRWTPERKLELENESSESKRNETIGQMWSGKMESTRSRTSSSSGRLGRSDDCDILPF
ADRRRFFEETSRKLSQSVTNLSNLTSRSQRLDKPGRMNHPSSPEPHEIAAHLGRRRFSYQ
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DVPYINSLDNGRQFISNQQDQEKTRQRLIEREQEREREQERLKEQEKLREQEREKERLRK
ERENEQQRLKDWEERQRLLQREQEWESVRESVHSEHNTSSDTVPHSLSHDVYRKQPPSP
QIPSSLQMSEPLYSSTTTNVQKPCSAFHPVTTQHNRYDGYQVNPPYNPRNYTPDELFCCL
KYSKYILQAQYVREQEKTRKINRNFSLTERDYPRSRRDFKTVDGANVPGFVRTGGNSITS
GRNEEHLFTPLRNRAMSENNLCVETQHYQNHSSSSGVSRMRSSTLSDLDENTVSVGEIK
KKKGPPPPRPPPPKWDQFHKRRASHHSLFSSTSHYSSPTASPPRPQPQTCTSRPPSVSEMS
RQRSYSLPPRDMSESLHCCRQEYSVAPSSPAFTRRAFKPVALPPREMDYNTRREVHQPEP
CTRIPIHPAAAPEEPRATHLKPTFPDHGVEWDRSSPHYPTHGTSRTPEVPSNSFSAGPLCP
ESYFSMNNFQLQPQQAGFPITAHKTQIIPSQGPEDGDLPLETDIDEICENEQAERKETVDR
MEMQGFARPVMVLETDIDHTPEEAAPSAISIRGPRGSLVDSILEDEYGVSRKELLGELFP
HSVNAEMSGDGWRGGYPISGGTLERFDNLIRQAFHFFEVLKPSRLNTTAPQVSRSTCYDI
SADNPQLLAKLREISERKEEDEELNYKKQLMESLRKKLTVLREAQRGLQEDIRANAQLG
DEVESLVLAICKPNEVDKYRMFIGDLDKVTSLLLSLSGRLIRVESALDCVDPETGHQERL
QLLEKKKQLLVQMGEAQELKEHVDRREQAVCRVLGCCLTPEQMRDYGHFVKMKAAL
LVEQRQLDDKIRLGEEQLRGLRESLGLGFGMAYGHY 
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A.2 PROTEIN SEQUENCE FOR XENOPUS TROPICALUS SHROOM4 
MDPQPADGSSQCIHVQLQGGAPWGFTLKGGLEHGEPLIISKIENGGKASMCEKMEVGDE
LVNINGTPLYGSRQEALILIKGSYKILRMIVRRRNLSVIRPHSWHLAKLTEVHPDVASMQ
YPTDAFSLSWHSGCENSELPMQWNPLSRHCSTDKSSSIGSMESLDQPGHNYYEGTLSPID
PSMYQNKRDSAYSSFSASSNASDYTLSARAEESSQMDCVADSSKPCDGRYLHTGQGAIE
IQQETSSLSPSEHQQRPSSFPFDANHLSFIKSPPQPPIRRDSLRASKNQICHGERRRASAPG
DSLQISGMWSSENQQHKNSDTSQCKCGIEFCTVHLKNGLSSDQYYMLSSQTDGGNQST
DQLALSDREMPSCCTEMQSRWPRDGRNIKQTINKEMENSSYHSAQTVKTVKDSLSKHP
SCLHMKSSSLPQSEQEEVSVQTKFHRKEWRNTLLQENFQCQTSECNGISSQELKCNINRD
SEIYQVDTLTDTGDFSQLSGKNKEQSQHITTLERSVSEPNEVRESFPVLLPKHSVGGMRS
SCSSETLLEESHEQEESQGPTKKPGSSRHRSAQMRRRSDRFATNLRNEIQRRKAQLQKN
KGSSVLLCGEEPVEEREEPTESQSPPRPMPPPPPPKNKSRLLELKRANAEQFHKGTDHQH
LEQNKQSLPSNRDTDKDNQKTEENSLNAVENVTRANDKSLISKSRLQNESNKSFVYDPR
QKDHQRVSSELNNESTMPSAENCREEWRTREPDFQRQHSKCLEQREPELGNVAESSATT
VRWNEVSRASPNPDVKVSHEMWRASSSLSINSVGSQTENFRGIGVESHSHYSGHKSLDA
DASFNGLLSSKEQLYSDGSSNDDWRISCLDNEEPMQRGREMMFSEPGRSSDHTSLFAAQ
WRSRHSSSDFEDPHVQQMPNGGRWKWSPEHKLLPHPQLSKGSPPDVSVVHAEGASLPN
RVASEENVLMPFADRRRFFENSSKVPNVSHIPLQIKSNKNNYCPSFPDPPLSQKVVSALR
RHSVDHTYHPSSPNRQDSALPYSDYCVNHTVDPLLCCSQGGHAAEYIHHPTGYGCRVH
ESCHCCSSDVCPALVKRNMPMSHLSCHFLHHHHHHHQWSRCGDYLCPAQHSTLEEGTS
LHGDPWHLQKPVLQEVPLKEWTQQLKIPNRKCSQSGSDLCHSNSGFHRAGPFRPCCDNS
EQDFPQCYRTVSSYDLSCEHSIRPELSSHHDEPSDQNLGRGRAYSVSQLNLDCLALRDK
KETSLSKLEEHMPSALAKKQKPPRPPPPNWDKYKERRASHQLTNSILSRHRENSVGSGH
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SISMEAVRQRSQSLPMERILLKANENYHPSSECEHPQIRDCSPVPSDLRPAHQEPDTSADT
VSTTFEHARQEPFSDCRNSPRDASPPRTDHLVPSDPVTSSHHQTTDFYSPLEGGSIEEPSN
SVAEESEDGVIPPKSTHDHISPDIPEREHPANLLDGFDSGYRHYEDEWSTDRESEISIPERY
EFQPISPPPVCGAVSPTSCAAYYNTSAAKAELLNKMKELPGLQEEVGDQEEVEEEDELSL
KKVQLIESISRKVSVLHEAQQGLQEDINANTTLGCEMADLLKNLCKPNEYEKFRTFIGDL
EKVVNLLLSLSGRLARVESVLSSEDPEPSVDEKLNLLEKKKQLTEQLEDAKELRAHVTR
REHMVLESVSRYLNEEQLQDYHHYVKMTSALIVEQRELEDKIRLGEEQLRCLRESL 
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